

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 April 2007 (12.04.2007)

PCT

(10) International Publication Number
WO 2007/039297 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 9/00 (2006.01)
A61K 31/437 (2006.01) A61P 3/10 (2006.01)
A61P 37/00 (2006.01) A61P 11/00 (2006.01)

C/Verge de Montserrat 6-8, 3^o2a, E-08980 Sant Feliu de Llobregat (Barcelona) (ES). PAREDES APARICIO, Sergio [ES/ES]; C/Navas de Tolosa 259, 5^o1a, E-08026 Barcelona (ES).

(21) International Application Number:

PCT/EP2006/009620

(74) Agents: WINKLER, Andreas et al.; Boehmert & Boehmert Anwaltssozietät, Hollerallee 32, 28209 Bremen (DE).

(22) International Filing Date: 5 October 2006 (05.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

P200502433 6 October 2005 (06.10.2005) ES

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): LABORATORIOS ALMIRALL, S.A. [ES/ES]; Ronda del General Mitre 151, E-08022 Barcelona (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): VIDAL JUAN, Bernat [ES/ES]; C/Font, 11, E-08396 St. Cebrià de Vallalta (Barcelona) (ES). FONQUERNA POU, Silvia [ES/ES]; Pg de l'Havana 2-4, esc D, baixos 3, E-08030 Barcelona (ES). EASTWOOD, Paul, Robert [GB/ES]; C/Palencia, 33, 2a 1^o, E-08191 Rubi (Barcelona) (ES). AIGUADE BOSCH, Jose [ES/ES]; C/Sardenya 379, 2^o2a, E-08025 Barcelona (ES). CARDUS FIGUERAS, Aranzazu [ES/ES]; C/Balmes 14, E-08780 Pallejà (Barcelona) (ES). CARRANCO MORUNO, Ines [ES/ES]; C/Eusebi Güell 98 1^o4a, E-08830 Sant Boi de Llobregat (Barcelona) (ES). GONZALEZ RODRIGUEZ, Jacob [ES/ES];


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMIDAZOPYRIDINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS



(57) Abstract: New imidazopyridine derivatives of formula (I) are disclosed as antagonists of the A_{2B} adenosine receptor.

WO 2007/039297 A1

IMIDAZOPYRIDINE DERIVATIVES AS A_{2B} ADENOSINE RECEPTOR ANTAGONISTS

The present invention relates to new antagonists of the A_{2B} adenosine receptor. These compounds are useful in the treatment, prevention or suppression of diseases and disorders known to be susceptible to improvement by antagonism of the A_{2B} adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, retinopathy, diabetes mellitus, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases.

10

Adenosine regulates several physiological functions through specific cell membrane receptors, which are members of the G-protein coupled receptor family. Four distinct adenosine receptors have been identified and classified: A₁, A_{2A}, A_{2B} and A₃.

15 The A_{2B} adenosine receptor subtype (see Feoktistov, I., Biaggioni, I. *Pharmacol. Rev.* 1997, 49, 381-402) has been identified in a variety of human and murine tissues and is involved in the regulation of vascular tone, smooth muscle growth, angiogenesis, hepatic glucose production, bowel movement, intestinal secretion, and mast cell degranulation.


20 In view of the physiological effects mediated by adenosine receptor activation, several A_{2B} receptor antagonists have been recently disclosed for the treatment or prevention of, asthma, bronchoconstriction, allergic diseases, hypertension, atherosclerosis, reperfusion injury, myocardial ischemia, retinopathy, inflammation, gastrointestinal tract disorders, cell proliferation diseases and/or diabetes mellitus. See for example WO2005070926, 25 WO2005042534, WO2005021548, WO2004106337, US2004176399, US2003229106, WO03002566, WO03/063800, WO03/042214, WO 03/035639, WO02/42298, EP 1283056, WO 01/16134, WO 01/02400, WO01/60350, WO 00/73307 or *Br. J. Pharmacol.* 2005, 145, 1009-1015.

30 It has now been found that certain imidazopyridine derivatives are novel potent antagonists of the A_{2B} adenosine receptor and can therefore be used in the treatment or prevention of these diseases.

Further objectives of the present invention are to provide a method for preparing said 35 compounds; pharmaceutical compositions comprising an effective amount of said

compounds; the use of the compounds in the manufacture of a medicament for the treatment of pathological conditions or diseases susceptible to improvement by antagonism of the A_{2B} adenosine receptor; and methods of treatment of pathological conditions or diseases susceptible to amelioration by antagonism of the A_{2B} adenosine receptor comprising the administration of the compounds of the invention to a subject in need of treatment.

Thus, the present invention is directed to new imidazopyridine derivatives of formula (I)



10 wherein:

A represents a monocyclic nitrogen-containing heteroaryl group optionally substituted by one or more substituents independently selected from the group comprising halogen atoms, C₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₄alkyl, C₁₋₄alkoxy, aryl-C₁₋₄alkoxy, C₁₋₄alkylthio, mono or di-C₁₋₄alkylamino, trifluoromethyl, hydroxy and cyano groups;

B represents a monocyclic nitrogen-containing heteroaryl group optionally substituted by one or more substituents independently selected from the group comprising halogen atoms, C₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₄alkyl, C₁₋₄alkoxy, aryl-C₁₋₄alkoxy, C₁₋₄alkylthio, mono or di-C₁₋₄alkylamino, trifluoromethyl, hydroxy and cyano groups;

L represents a linking group selected from the group comprising direct bond, -(CRR')_n-, -NR-, -S-, -O- and -CO-; wherein n is an integer from 0 to 2;

25 G represent a group selected from the group comprising -H, -OH, C₃₋₇ cycloalkyl; C₁₋₆ alkyl, aryl, heteroaryl and nitrogen-containing saturated heterocyclic rings, wherein the aryl, heteroaryl and nitrogen-containing saturated heterocyclic groups are unsubstituted or substituted by one or more groups selected from halogen atoms, C₁₋₄ alkyl, C₁₋₄ alkylthio, C₁₋₄ alkoxy, mono- or di-C₁₋₄ alkylamino, cyano, trifluoromethyl, -COOH and -CO-O-C₁₋₄ alkyl groups;

R and R' are independently selected from hydrogen atoms and C₁₋₄ alkyl groups;

and the pharmaceutically acceptable salts and N-oxides thereof.

As used herein the terms alkyl or lower alkyl embrace optionally substituted, linear or branched hydrocarbon radicals having 1 to 8, preferably 1 to 6 and more preferably 1 to 4
5 carbon atoms. Preferred substituents on the alkyl groups are halogen atoms and hydroxy groups.

Examples include methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *sec*-butyl and *tert*-butyl, *n*-pentyl, 1-methylbutyl, 2-methylbutyl, isopentyl, 1-ethylpropyl, 1,1-dimethylpropyl, 1,2-
10 dimethylpropyl, *n*-hexyl, 1-ethylbutyl, 2-ethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 2-methylpentyl, 3-methylpentyl and iso-hexyl radicals.

As used herein, the term cycloalkyl embraces saturated carbocyclic radicals and, unless
15 otherwise specified, a cycloalkyl radical typically has from 3 to 7 carbon atoms.

Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. When a cycloalkyl radical carries 2 or more substituents, the substituents may be the same or different. Preferred substituents on the cycloalkyl groups are halogen atoms and hydroxy
20 groups.

As used herein, unless otherwise provided, the term aryl radical embraces typically a C₅-C₁₄ monocyclic or polycyclic aryl radical such as phenyl or naphthyl, anthranyl or phenanthryl. Optionally substituted phenyl is preferred. When an aryl radical carries 2 or
25 more substituents, the substituents may be the same or different. Preferred substituents on the aryl radicals are halogen atoms and C₁₋₄ alkyl, C₁₋₄ alkylthio, C₁₋₄ alkoxy, mono- or di-C₁₋₄ alkylamino, cyano, trifluoromethyl, -COOH and -CO-O-C₁₋₄ alkyl groups. Halogen atoms are particularly preferred.

30 As used herein, unless otherwise provided, the term heteroaryl radical embraces typically a 5- to 14- membered ring system comprising at least one heteroaromatic ring and containing at least one heteroatom selected from O, S and N. The term nitrogen-containing heteroaryl is used to designate heteroaryl groups which comprise at least one nitrogen atom forming part of the ring system. A heteroaryl radical may be a single ring or
35 two or more fused rings wherein at least one ring contains a heteroatom.

Examples of monocyclic heteroaryl radicals include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, furyl, oxadiazolyl, oxazolyl, imidazolyl, thiazolyl, thiadiazolyl, thienyl, pyrrolyl, pyridinyl, triazolyl, imidazolidinyl and pyrazolyl radicals. Pyridyl, thienyl, furyl, pyridazinyl and pyrimidinyl radicals are preferred. Pyridyl and pyrimidinyl are the most preferred.

When a heteroaryl radical carries 2 or more substituents, the substituents may be the same or different. Preferred substituents on the heteroaryl radicals are halogen atoms and C₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₄alkyl, C₁₋₄alkoxy, aryl-C₁₋₄alkoxy, C₁₋₄alkylthio, mono or di-C₁₋₄alkylamino, trifluoromethyl, hydroxy -COOH, -CO-O-C₁₋₄ alkyl and cyano groups.

As used herein, the term heterocyclic group embraces typically a non-aromatic, saturated or unsaturated C₃-C₁₀ carbocyclic ring, such as a 5, 6 or 7 membered radical, in which one or more, for example 1, 2, 3 or 4 of the carbon atoms, preferably 1 or 2, of the carbon atoms are replaced by a heteroatom selected from N, O and S. The term nitrogen-containing saturated heterocyclic ring is used to designate saturated heterocyclic groups which comprise at least one nitrogen atom forming part of the ring system. A heterocyclic radical may be a single ring or two or more fused rings wherein at least one ring contains a heteroatom. When a heterocyclyl radical carries 2 or more substituents, the substituents may be the same or different. Preferred substituents on the heterocyclic radicals are halogen atoms and C₁₋₄ alkyl, C₁₋₄ alkylthio, C₁₋₄ alkoxy, mono- or di-C₁₋₄ alkylamino, cyano, trifluoromethyl, -COOH and -CO-O-C₁₋₄ alkyl groups.

Examples of monocyclic, nitrogen-containing heterocyclic radicals include piperidyl, pyrrolidyl, pyrrolinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyrrolyl, pyrazolinyl, pirazolidinyl, quinuclidinyl, pyrazolyl. Piperidyl, piperazinyl and morpholinyl are preferred radicals.

As used herein, some of the atoms, radicals, moieties, chains or cycles present in the general structures of the invention are "optionally substituted". This means that these atoms, radicals, moieties, chains or cycles can be either unsubstituted or substituted in any position by one or more, for example 1, 2, 3 or 4, substituents, whereby the hydrogen atoms bound to the unsubstituted atoms, radicals, moieties, chains or cycles are replaced

by chemically acceptable atoms, radicals, moieties, chains or cycles. When two or more substituents are present, each substituent may be the same or different.

As used herein, the term halogen atom embraces chlorine, fluorine, bromine or iodine atoms typically a fluorine, chlorine or bromine atom, most preferably chlorine or fluorine. The term halo when used as a prefix has the same meaning.

As used herein, the term pharmaceutically acceptable salt embraces salts with a pharmaceutically acceptable acid or base. Pharmaceutically acceptable acids include both inorganic acids, for example hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic, hydroiodic and nitric acid and organic acids, for example citric, fumaric, maleic, malic, mandelic, ascorbic, oxalic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or *p*-toluenesulphonic acid. Pharmaceutically acceptable bases include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g. calcium or magnesium) hydroxides and organic bases, for example alkyl amines, arylalkyl amines and heterocyclic amines.

Other preferred salts according to the invention are quaternary ammonium compounds wherein an equivalent of an anion (X-) is associated with the positive charge of the N atom. X- may be an anion of various mineral acids such as, for example, chloride, bromide, iodide, sulphate, nitrate, phosphate, or an anion of an organic acid such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, trifluoroacetate, methanesulphonate and *p*-toluenesulphonate. X- is preferably an anion selected from chloride, bromide, iodide, sulphate, nitrate, acetate, maleate, oxalate, succinate or trifluoroacetate. More preferably X- is chloride, bromide, trifluoroacetate or methanesulphonate.

As used herein, an N-oxide is formed from the tertiary basic amines or imines present in the molecule, using a convenient oxidising agent.

Preferred compounds of the invention are those wherein A represents an optionally substituted pyridine or an optionally substituted oxazole group. It is further preferred that A represents a pyridine ring either unsubstituted or substituted with one halogen atom.

In another embodiment of the present invention the group B represents an optionally substituted pyridine or pyrimidine group. It is further preferred that B represents a pyridine group which is unsubstituted or substituted by one or more halogen atoms

- 5 In an alternative embodiment of the present invention -L-G represents a moiety selected from the group consisting of hydrogen atoms, hydroxyl groups, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted benzyl, optionally substituted benzoyl, C₃₋₇ cycloalkyl, C₁₋₆ alkyl, optionally substituted morpholino, optionally substituted piperidino and optionally substituted piperazine groups wherein optionally substituted
 - 10 groups may carry from 0 to 2 substituents selected from the group consisting of halogen atoms, C₁₋₄alkyl, C₁₋₄alkylthio, C₁₋₄alkoxy, mono or di-C₁₋₄alkylamino, cyano, -(CO)OH, -(CO)O-C₁₋₄alkyl, trifluoromethyl, piperidinylmethyl, pyridinylmethyl, phenylamino and piperidinylamino.
- 15 Particular individual compounds of the invention for their use in the manufacture of a medicament for the treatment of a pathological condition or disease susceptible to improvement by antagonism of the A_{2B} adenosine receptor include:
 - 6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-1,3-dihydro-2H-imidazo[4,5-*b*]pyridin-2-one
 - 20 2-Cyclopropyl-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-*b*]pyridine
 - 2-Cyclohexyl-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-*b*]pyridine
 - 6-(3-Fluoropyridin-4-yl)-2-methyl-5-pyridin-3-yl-3H-imidazo[4,5-*b*]pyridine
 - 2-(4-Fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-*b*]pyridine
 - 6-(3-Fluoropyridin-4-yl)-2-(4-methoxyphenyl)-5-pyridin-3-yl-3H-imidazo[4,5-*b*]pyridine
 - 25 *N*-{4-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-*b*]pyridin-2-yl]phenyl}-*N,N*-dimethylamine
 - 6-(3-Fluoropyridin-4-yl)-2-(4-*tert*-butylphenyl)-5-pyridin-3-yl-3H-imidazo[4,5-*b*]pyridine
 - 6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-[4-(trifluoromethyl)phenyl]-3H-imidazo[4,5-*b*]pyridine
 - 30 Methyl 4-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-*b*]pyridin-2-yl]benzoate
 - 4-[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-*b*]pyridin-2-yl]benzoic acid
 - 6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-pyridin-4-yl-3H-imidazo[4,5-*b*]pyridine
 - 2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-*b*]pyridine

- 6-(3-Fluoropyridin-4-yl)-2-[3-fluoro-4-(trifluoromethyl)phenyl]-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
- 2-(2,4-Dichloro-5-fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
- 5 2-(4-Fluorobenzyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
- 2-[1-(4-Chlorophenyl)-1-methylethyl]-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
- (3,5-Difluorophenyl)[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]methanone
- 10 *N*-(4-chlorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-amine
- 2-(4-Fluorophenyl)-5-pyridin-3-yl-6-pyridin-4-yl-3*H*-imidazo[4,5-*b*]pyridine
- 6-(3-Chloropyridin-4-yl)-5-pyridin-3-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 5,6-Dipyridin-4-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 5-(3-Fluoropyridin-4-yl)-6-pyridin-4-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 15 5-(3-Chloropyridin-4-yl)-6-pyridin-4-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 5-(3-Chloropyridin-4-yl)-2-(4-fluorophenyl)-6-pyridin-4-yl-3*H*-imidazo[4,5-*b*]pyridine
- 6-(3-Chloropyridin-4-yl)-5-pyridin-4-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 6-(3-Chloropyridin-4-yl)-2-(4-fluorophenyl)-5-pyridin-4-yl-3*H*-imidazo[4,5-*b*]pyridine
- 5-(3-Chloropyridin-4-yl)-2-(4-fluorophenyl)-6-(3-fluoropyridin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine
- 20 *b*]pyridine
- 5,6-Bis(3-chloropyridin-4-yl)-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 5-(1,3-Oxazol-2-yl)-6-pyridin-4-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 5-(1,3-Oxazol-2-yl)-6-pyridin-4-yl-3*H*-imidazo[4,5-*b*]pyridine
- 6-(3-Fluoropyridin-4-yl)-5-(1,3-oxazol-2-yl)-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 25 6-(3-Fluoropyridin-4-yl)-5-(1,3-oxazol-2-yl)-3*H*-imidazo[4,5-*b*]pyridine
- 5-(1,3-Oxazol-5-yl)-6-pyridin-4-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 5-(1,3-Oxazol-5-yl)-6-pyridin-4-yl-3*H*-imidazo[4,5-*b*]pyridine
- 6-(3-Fluoropyridin-4-yl)-5-(1,3-oxazol-5-yl)-3*H*-imidazo[4,5-*b*]pyridine
- 2-(3-Fluoro-4-methylphenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine.
- 30 *b*]pyridine.
- 2-(3-Fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
- 6-(3-Fluoropyridin-4-yl)-2,5-dipyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
- 6-(3-Fluoropyridin-4-yl)-2-pyrazin-2-yl-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
- 3-[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]benzonitrile
- 35 3-[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]benzoic acid;

- 6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-pyrimidin-5-yl-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-2-pyridin-2-yl-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
2-(3-Chloropyridin-4-yl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-2-(1-methyl-1*H*-imidazol-5-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-
5 *b*]pyridine
6-(3-Fluoropyridin-4-yl)-2-(methylthio)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
1-[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]-1*H*-pyrazole-4-
carboxylic acid
6-(3-Fluoropyridin-4-yl)-2-(1-methyl-1*H*-pyrazol-5-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-
10 *b*]pyridine
6-(3-Fluoropyridin-4-yl)-2-[1-methyl-3-(trifluoromethyl)-1*H*-pyrazol-5-yl]-5-pyridin-3-yl-3*H*-
imidazo[4,5-*b*]pyridine
2-(3,5-Dimethyl-1*H*-pyrazol-1-yl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-
b]pyridine
15 6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-(4*H*-1,2,4-triazol-3-yl)-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-2-morpholin-4-yl-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-2-piperidin-1-yl-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-2-(4-methylpiperazin-1-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-amine
20 6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-[3-(trifluoromethyl)benzyl]-3*H*-imidazo[4,5-
b]pyridine
6-(3-Fluoropyridin-4-yl)-2-(2-phenylethyl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-(2-pyridin-3-ylethyl)-3*H*-imidazo[4,5-*b*]pyridine
2-[1-(4-Chlorophenyl)ethyl]-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
25 4-{2-[6-(3-Fluoro-pyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]-ethyl}-benzoic
acid
6-(3-Fluoropyridin-4-yl)-*N*,5-dipyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-amine
N-(4-Fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-amine
4-[[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]amino]benzoic acid
30 6-(3,5-Difluoropyridin-4-yl)-2-(4-fluorophenyl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
4-[6-(3,5-Difluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]benzoic acid
6-(3,5-Difluoropyridin-4-yl)-5-pyridin-3-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one


Of outstanding interest are:

- 5-(3-Fluoropyridin-4-yl)-6-pyridin-4-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
 6-(3-Fluoropyridin-4-yl)-5-(1,3-oxazol-2-yl)-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
 4-[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]benzoic acid
 6-(3-Fluoropyridin-4-yl)-2-(4-methoxyphenyl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
 5 *N*-{4-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]phenyl}-*N,N*-
 dimethylamine
 6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-pyridin-4-yl-3*H*-imidazo[4,5-*b*]pyridine
 2-(4-Fluorobenzyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
 2-(3-Fluoro-4-methylphenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-
 10 *b*]pyridine.
 2-(3-Fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
 6-(3-Fluoropyridin-4-yl)-2,5-dipyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
 6-(3-Fluoropyridin-4-yl)-2-(1-methyl-1*H*-imidazol-5-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-
b]pyridine
 15 6-(3,5-Difluoropyridin-4-yl)-2-(4-fluorophenyl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
 4-[6-(3,5-Difluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]benzoic acid
 6-(3,5-Difluoropyridin-4-yl)-5-pyridin-3-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one

Compounds of general formula (I) and in particular those wherein A, B are as defined in
 20 claim 1 and L represents a linking group selected from the group comprising direct bond, -
 (CRR')_n or -CO- and G represents a group selected from the group comprising -H, -OH
 (general formula (XI)), C₃₋₇ cycloalkyl; C₁₋₄ alkyl, aryl, heteroaryl and nitrogen-containing
 saturated heterocyclic rings (general formula (XII)) may be prepared following the
 synthetic scheme depicted in scheme 1.

25

SCHEME 1

**Step a**

- Halogenation of 6-chloro-3-nitropyridin-2-amine (II) using reagents such as I_2 or *N*-halosuccinimide in polar aprotic solvents such as DMF or mixtures of solvents DMSO:H₂O and at temperatures ranging from 0°C to 100°C yields dihalonitropyridin-2-amines (III).

Step b

- Regioselective Suzuki or Stille-type coupling with the boronic acid or boronate derivative or the trialkyltin (preferably tributyltin) derivative of B using a palladium catalyst such as tetrakis(triphenylphosphine)palladium(0), [1,1'-bis(diphenylphosphino)ferrocene] palladium(II)dichloride dichloromethane complex (1:1) or bis(triphenylphosphine) palladium(II)dichloride in solvents such as toluene, dioxane in the presence of an aqueous solution of a base such as sodium or caesium carbonate and at a temperature between 25°C to 110°C, or in solvents such as DMF using a copper catalyst and at a temperature between 25°C to 150°C provides compounds of general formula (IV).

Step c

A further Suzuki, Negishi or Stille-type coupling using the corresponding boronic acid or boronate derivative, the arylzinc derivative or the trialkyltin (preferably tributyltin) derivative of A under the standard procedures for Pd catalyzed reactions described above provides the 2-amino-3-nitropyridines (V).

5

Steps d and e

Alternatively, regioselective Suzuki, Stille or Negishi-type coupling of the corresponding derivative of A with 6-chloro-3-nitropyridin-2-amine (II), using the standard procedures for Pd catalyzed reactions described above, provides compounds of general formula (VI),

10 which upon a halogenation step using the same protocols described above provides compounds of general formula (VII).

Steps f and g

Dihalopyridine derivatives (IX) are prepared by halogenation of 6-halopyridine derivatives (VIII) using reagents such as Br₂ or N-halosuccinimide in polar aprotic solvents such as DMF and at temperatures ranging from 0°C to 100°C, to yield dihaloaminopyridines (not shown). These products are in turn nitrated in a two step process involving nitration of the amino group in a mixture of sulphuric and nitric acid in a temperature range between –

20 10°C to 0°C followed by a sulfuric acid promoted rearrangement of the nitro group to produce compounds of formula (IX). A further regioselective Suzuki, Negishi or Stille-type coupling with the corresponding derivative of A and using the standard procedures for Pd catalyzed reactions described above provides compounds of general formula (VII).

Steps h and i

25 A further Suzuki or Stille-type coupling with the corresponding derivative of B described above provides compounds of general formula (V). Reduction of the nitro group using standard hydrogenation conditions in the presence of hydrogen and using Pd on carbon as a catalyst provides the diamino derivatives (X). Alternatively, the reduction of the nitro group can also be accomplished by treatment with iron in the presence of hydrochloric acid in solvents such as ethanol.

30

Step j

Treatment of (X) with carbonylating agents such as carbonyldiimidazole in polar aprotic solvents such as DMF or THF in the presence or absence of a base such as sodium

hydride or triethylamine and heating at temperatures between 50°C and 200°C provides the imidazolone compounds (Ib).

Steps k and l


- 5 Treatment of compounds of formula (X) with acylating agents such as anhydrides, acid chlorides or acylcarbonates in apolar organic solvents such as THF and in the presence of a convenient organic base (such as triethylamine) or inorganic base, and eventually acylating with carboxylic acids using coupling agents such as diethylcarbodiimide, yields the compounds of formula (XIII), which can be converted into the compounds of formula
- 10 (Ia) by acid (for example acetic acid) or base (for example sodium hydroxide) catalyzed cyclization at temperatures between 70°C and 200°C.

Step m

- Alternatively, diamino derivatives (X) can be cyclized to the imidazopyridines (Ia) by
- 15 heating in neat trialkylorthoacid or in an acetic acid solution of the orthoacid derivatives or by using an acyl chloride (Cl-CO-L-G) and a solvent such as pyridine and at temperatures between 70°C and 200°C.

- By following another synthetic pathway (Scheme 2), intermediates (V) can also be
- 20 accessed starting from 2,6-dichloro-3-nitropyridine (XIV)

SCHEME 2



Steps a to e

Displacement of the 2-chloro functionality of (XIV) with an alcohol, preferably methyl alcohol, in the presence of a base, preferably sodium hydride, in an organic solvent such as xylene leads to compounds of formula (XV). Reaction of (XV) under typical cross-coupling conditions with, for example, an aryl boronic acid or an aryl stannane, preferably a tributyl stannane, in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium(0) or [1,1'-bis(diphenylphosphino)ferrocene] palladium(II)dichloride dichloromethane complex (1:1) in solvents such as toluene or dioxane at temperatures ranging from 80°C -120°C gives rise to intermediates of type (XVI). Displacement of the alkoxy functionality of (XVI) by heating with concentrated aqueous ammonia at temperatures ranging from 80°C -120°C in a sealed vessel gives rise to intermediates of type (VI) which can be elaborated to intermediates (V) by using the protocols outlined in Scheme 1.

Steps f to j


Intermediates of type (V) can also be accessed via an alternative route (Scheme 2) starting from 2,6-dichloro-3-nitropyridine (XIV). Displacement of the 2-chloro functionality with a suitable secondary aliphatic amine, such as *N,N*-di(4-methoxy)benzylamine, in a suitable solvent such as chloroform in the presence of an organic base such as triethylamine, at temperatures ranging from 0°C to 25°C gives rise to intermediates of type (XVII), which may be considered a nitrogen protected version of compound (II). Reaction of (XVII)

under typical cross-coupling conditions with, for example, an aryl boronic acid or an aryl stannane in the presence of a palladium catalyst such as such as tetrakis(triphenylphosphine)palladium(0) or [1,1'-bis(diphenylphosphino)ferrocene] palladium(II)dichloride dichloromethane complex (1:1) in solvents such as toluene or dioxane at temperatures ranging from 80°C -120°C gives rise to intermediates of type (XVIII) which can be halogenated using reagents such as Br₂ or *N*-halosuccinimide in polar aprotic solvents such as DMF and at temperatures ranging from 0°C to 100°C, to yield compounds (XIX). A second palladium catalyzed cross coupling reaction give rise to intermediates (XX) which can be deprotected with, for example, trifluoroacetic acid in dichloromethane, to give the desired intermediates (V).

Compounds of general formula (Ib) corresponding to compounds of formula (I) wherein L is a direct bond, G is a hydroxy group and A and B as as defined in claim 1, may be prepared following the synthetic scheme depicted in scheme 3.

15

SCHEME 3

Step a

The aldehydes of formula (XXIV) are reacted with the halomethyl derivatives of formula (XXV) to yield the ketones of formula (XXIII) either *via* cyanohydrin intermediates or in a two step process involving addition of an organometallic derivative of (XXV), preferably magnesium or zinc derivative, followed by reoxidation of the resulting alcohol using
5 oxidizing agents such as manganese (IV) oxide.

Step b

Alternatively the ketones of formula (XXIII) may be obtained by condensation of the ethyl esters of formula (XXI) with the compounds of formula (XXII). This reaction is conveniently
10 carried out in the presence of an organic base such as lithium bis(trimethylsilyl)amide in a range of temperature about -10°C to about 50°C and in organic aprotic solvents, preferably tetrahydrofuran or diethyl ether.

Steps c to e

15 The ketones of formula (XXIII) are then reacted in neat *N,N*-dimethylformamide dialkyl acetal, such as dimethylacetal, at a temperature range between room temperature and 150°C to yield the dimethylamino α,β unsaturated ketone of formula (XXVI) which can be converted into the 2-oxo-1,2-dihydropyridine-3-carbonitriles of formula (XXVII) by cyclization in the presence of cyanoacetamide using alkoxides such as sodium methoxide
20 in polar aprotic solvents such as dimethylformamide and at temperatures between 50°C to 150°C. These compounds may be converted into the 2-chloronicotinonitriles of formula (XXVIII) by treatment of the resulting pyridone (XXVII) with chlorinating agents such as POCl₃, PCl₅ and PhPOCl₂ or by using a combination of such reagents.

Steps f to h


2-Chloronicotinonitriles of formula (XXVIII) may be reacted with a saturated solution of ammonia in an organic solvent, preferably ethanol, at a temperature between 25°C to 150°C to yield the compounds of formula (XXIX). Hydrolysis of compounds (XXIX) to the carboxylic acid of formula (XXX) can be achieved with a base such as potassium
30 hydroxide in aqueous or organic solvents such as ethylene glycol and at a temperature between 50°C to 200°C. Alternatively this conversion could be achieved under aqueous acidic media such as 6M sulphuric acid. These compounds may be subjected to Curtius rearrangement by formation and rearrangement of the acyl azide derivative which may be formed by reacting (XXX) with diphenylphosphoryl azide (or sodium azide with activated
35 acid) in an organic solvent compatible with these reaction conditions (e.g. dioxane) and at a range of temperature between 0°C to 30°C followed by heating at a temperature ranging

between 50°C to 200°C, with *in situ* formation of the target pyridoimidazolone ring yielding compounds of formula (Ib).

Compounds of general formula (I) and in particular those wherein A, B are as defined in claim 1 and L represents a linking group selected from the group comprising -NR-, -S- or -O- and G represents a group selected from the group comprising C₃₋₇ cycloalkyl; C₁₋₄ alkyl, aryl, heteroaryl and nitrogen-containing saturated heterocyclic rings may be prepared following the synthetic scheme depicted in scheme 4.

10

SCHEME 4



15 Steps a to c

Compounds of general formula (XXXI) can be prepared from imidazolones (Ib) using reagents such as oxalyl chloride, phosphorus oxychloride, phosphorus pentachloride or a combination of them at a temperature ranging from 20° to 150°C in a solvent like

dichloromethane or acetonitrile. Alternatively, compounds (XXXI) may be prepared by treating imidazolones (Ib) with sodium hydride and then with trifluoromethansulfonyl chloride, trifluoromethansulphonyl anhydride or *N*-phenyl-bis(trifluoroethansulfonimide) in dimethylformamide at a range of temperatures between 20°C and 150°C. Compounds of
5 general formula (XXXI) can be treated with primary or secondary amines at a range of temperatures between 40° and 170°C to give compounds of general formula (Ic). Alternatively, compounds of general formula (Ic) may be obtained by heating imidazolones (Ib) in the presence of a primary or secondary amine and a dehydrating agent like magnesium sulphate or molecular sieves.

10

Steps d, e and i

On the other hand, compounds of general formula (Ie) can be prepared from imidazolones (Ib) using reagents such as oxalyl chloride or phosphorus chloride at a temperature ranging from 20° to 150°C and then with an aryl or alkyl thiol at a temperature between 60° to
15 150°C. Additionally, compounds of general formula (Ie) where G is an alkyl or cycloalkyl group can be prepared by reaction of diamines (X) with 1,1'-thiocarbonyldiimidazole followed by alkylation using the corresponding alkylhalides. Compounds (Ie) can then be heated up at a temperature between 60°C and 150°C in the presence of the primary or secondary amine to afford compounds of general formula (Ic). In some cases, oxidation to
20 the corresponding sulfone or the use of catalytic Lewis acid such as zinc chloride may be needed.

Steps f and g

Diamines (X) may be treated with alkyl or aryl isothiocyanates to give the thioureas of
25 general formula (XXXII). Thioureas of formula (XXXII) can be treated with alkylcarbodiimides at room temperature or with the assistance of the microwaves to give compounds of general formula (Ic). Alternatively, thioureas of general formula (XXXII) may be treated under reductive conditions such as mercury oxide and sulphur to give compounds of general formula (Ic).

30

Step h

Compounds of general formula (Id) can be prepared by treating compounds of formula (XXXI) with aryloxy or alkyloxy nucleophiles such as sodium methoxide or lithium phenyl. Alternatively, compounds of general formula (Id) may be prepared from imidazolones (Ib)
35 using sodium or potassium hydride and alkyl or arylalkyl halides or triflates in a solvent

such as dimethylformamide or tetrahydrofuran in a range of temperatures between -78° to 100°C.

EXPERIMENTAL

5

PHARMACOLOGICAL ACTIVITY

Adenosine 2B receptor subtype competition radioligand binding assay

- 10 A2B membranes were prepared from HEK293 cells stably expressing the human A2B receptor that were purchased from Euroscreen (ES-013-C). Competition assays were carried out incubating in polypropylene 96 well-plates (n° 267245, NUNC) containing 2 µl of either 1% DMSO solution, test compound or 100 µM 5'NECA (SIGMA E-2387) for non-specific binding, 100 µg of A2B-membranes (prepared in Tris-HCl 50 mM pH 6.5, 15 MgCl₂ 10 mM, EDTA 1 mM, benzamidine 0.1 mM; buffer A) and 35 nM [³H]-DPCPX (TRK1064, 128Ci/mmol, Amersham), in a total volume of 200 µl of buffer A + 2UI/ml adenosine deaminase, for 60 minutes at room temperature. At the end of the incubation, samples were transferred to a GF/C filter plates (Milipore MAFCN0B50) pretreated for 15 min. with 250 µl of Tris-HCl 50 mM pH 6.5 (Buffer B). Samples were then filtered 4 times 20 with 250 µl of buffer B. Samples were counted using 30 µl of Hisafe II (Perkin Elmer) in a Trilux counter.

Table 1 shows the binding activities of some of the compounds of the present invention determined using the adenosine 2B receptor subtype competition radioligand binding 25 assay described above.

TABLE 1

Example	K _i
6	0.8
7	1.7
11	8
12	1.8
16	24
23	7

32	24
37	2.2
38	2.8
39	3.8
46	9.5
65	2.8
66	23
67	26

The compounds of formula (I) have been tested according to the assay described above and have shown to be potent inhibitors of the A_{2B} adenosine receptor subtype. Preferred imidazopyridine derivatives of the invention possess a K_i value for the antagonism of A_{2B} (determined as defined above) of less than 50 nM, preferably less than 10 nM and more preferably less than 5 nM.

The imidazopyridine derivatives of the invention are useful in the treatment or prevention of diseases known to be susceptible to improvement by treatment with an antagonist of the A_{2B} adenosine receptor. Such diseases include but are not limited to asthma, chronic obstructive pulmonary disorder, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, retinopathy, diabetes mellitus, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases. Examples of autoimmune diseases which can be treated or prevented using the compounds of the invention are Addison's disease, autoimmune hemolytic anemia, Crohn's disease, Goodpasture's syndrome, Graves disease, Hashimoto's thyroiditis, idiopathic thrombocytopenic purpura, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, pernicious anemia, poststreptococcal glomerulonephritis, psoriasis, rheumatoid arthritis, scleroderma, Sjogren's syndrome, spontaneous infertility, and systemic lupus erythematosus.

Accordingly, the imidazopyridine derivatives of the invention and pharmaceutical compositions comprising such compounds and/or salts thereof may be used in a method of treatment of disorders of the human or animal body which comprises administering to a subject requiring such treatment an effective amount of imidazopyridine derivative of the invention or a pharmaceutically acceptable salt thereof.

When imidazopyridine derivatives of the invention are used for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disorder, pulmonary fibrosis or emphysema it may be advantageous to use them in combination with other active compounds known to be useful in the treatment of respiratory diseases such as (1)

5 antagonists of M3 muscarinic receptors, (2) β 2-agonists, (3) PDE4 inhibitors, (4) corticosteroids, (5) leukotriene D4 antagonists, (6) inhibitors of egfr-kinase, (7) p38 kinase inhibitors, (8) NK1 receptor agonists, (9) CRTh2 antagonists, (10) syk kinase inhibitors, (11) CCR3 antagonists and (12) VLA-4 antagonists.

10 Thus, the present invention also provides pharmaceutical compositions comprising a imidazopyridine derivative of the invention and another active compound selected from the groups consisting of (1) antagonists of M3 muscarinic receptors, (2) β 2-agonists, (3) PDE 4 inhibitors, (4) corticosteroids, (5) leukotriene D4 antagonists, (6) inhibitors of egfr-kinase, (7) p38 kinase inhibitors, (8) NK1 receptor agonists, (9) CRTh2 antagonists, (10)
15 syk kinase inhibitors , (11) CCR3 antagonists and (12) VLA-4 antagonists.

The present invention also provides pharmaceutical compositions which comprise, as an active ingredient, at least a imidazopyridine derivative of formula (I) in association with a pharmaceutically acceptable excipient such as a carrier or diluent. The active ingredient
20 may comprise 0.001% to 99% by weight, preferably 0.01% to 90% by weight of the composition depending upon the nature of the formulation and whether further dilution is to be made prior to application. Preferably the compositions are made up in a form suitable for oral, topical, nasal, rectal, percutaneous, injectable administration or inhalation.

25

The pharmaceutically acceptable excipients which are admixed with the active compound or salts of such compound, to form the compositions of this invention are well-known *per se* and the actual excipients used depend *inter alia* on the intended method of administering the compositions.

30

Compositions of this invention are preferably adapted for inhaled, injectable or oral administration. The compositions for oral administration may take the form of tablets, retard tablets, sublingual tablets, capsules or liquid preparations, such as mixtures, elixirs, syrups or suspensions. The compositions for inhalation may take the form of inhalation

aerosols, inhalation solutions or dry powders for inhalation all containing the compound of the invention; such preparations may be made by methods well-known in the art.

5 The diluents which may be used in the preparation of the compositions include those liquid and solid diluents which are compatible with the active ingredient, together with colouring or flavouring agents, if desired. Tablets or capsules may conveniently contain between 2 and 500 mg of active ingredient or the equivalent amount of a salt thereof.

10 The liquid composition adapted for oral use may be in the form of solutions or suspensions. The solutions may be aqueous solutions of a soluble salt or other derivative of the active compound in association with, for example, sucrose to form a syrup. The suspensions may comprise an insoluble active compound of the invention or a pharmaceutically acceptable salt thereof in association with water, together with a suspending agent or flavouring agent.

15 Compositions for parenteral injection may be prepared from soluble salts, which may or may not be freeze-dried and which may be dissolved in pyrogen free aqueous media or other appropriate parenteral injection fluid.

20 When the compositions are intended for inhalation they may be in the form of spray compositions for topical delivery to the lung by inhalation or in the form of dry powder compositions for topical delivery to the lung by inhalation.

25 The spray composition for inhalation may, for example, be formulated as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, such as a metered dose inhaler, with the use of a suitable liquefied propellant.

30 Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in different primary packaging systems (such as capsules and cartridges of for example gelatine or blisters of for example laminated aluminium foil), for use in an inhaler or insufflator. Packaging of the formulation may be suitable for unit dose or multi-dose delivery. In the case of multi-dose delivery, the formulation can be pre-metered or metered in use. Dry powder inhalers are thus classified into three groups: (a) single dose, (b) multiple unit dose and (c) multi dose devices.

35

Dry powder formulations generally contain a powder mix for inhalation of the compounds of the invention and a suitable powder base (carrier substance) such as lactose or starch. Use of lactose is preferred. Each capsule or cartridge may generally contain between 2 µg and 400 µg of each therapeutically active ingredient. Alternatively, the active ingredient (s) may be presented without excipients.

Effective doses are normally in the range of 2-2000 mg of active ingredient per day. Daily dosage may be administered in one or more treatments, preferably from 1 to 4 treatments, per day.

10

The syntheses of the compounds of the invention and of the intermediates for use therein are illustrated by the following Examples (1 to 36) including Preparation Examples (Intermediates 1 to 13) which do not limit the scope of the invention in any way.


15 ¹H Nuclear Magnetic Resonance Spectra were recorded on a Varian Mercury spectrometer operating at 200 MHz. Melting points were recorded using a Büchi B-540 apparatus. The chromatographic separations were obtained using a Waters 2795 system equipped with a Symmetry C18 (2.1 x 100 mm, 3.5 mm) column. As detectors a Micromass ZMD mass spectrometer using ES ionization and a Waters 996 Diode Array
20 detector were used. The mobile phase was formic acid (0.46 ml), ammonia (0.115 ml) and water (1000 ml) (A) and formic acid (0.4 ml), ammonia (0.1 ml), methanol (500 ml) and acetonitrile (500 ml) (B): initially from 0% to 95% of B in 20 min, and then 4 min. with 95% of B. The reequilibration time between two injections was 5 min. The flow rate was 0.4 ml/min. The injection volume was 5 µl. Diode array chromatograms were processed at
25 210 nm.

PREPARATION EXAMPLES

Intermediate 1:

30 **3''-Fluoro-3,2':3',4''-terpyridine-5',6'-diamine**

Step a:




5-Nitro-2,3'-bipyridin-6-amine

An oven dried resealable Schlenk tube was charged with 6-chloro-3-nitropyridin-2-amine (5 g, 28.81 mmol), 3-pyridineboronic acid (5.31 g, 43.2 mmol), dioxane (250 mL) and a 2M aqueous solution of cesium carbonate (43 mL, 86.4 mmol). The Schlenk tube was subjected to three cycles of evacuation-backfilling with argon, and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (2.3 g, 2.81 mmol) was added. After three new cycles of evacuation-backfilling with argon, the Schlenk tube was capped and placed in a 100°C oil bath. After 3h, the mixture was cooled, partitioned between water and ethyl acetate, the aqueous phase extracted twice with ethyl acetate, the organic layers washed with brine, dried (MgSO₄) and evaporated. The residue was purified by silica gel flash chromatography (95:5 dichloromethane/methanol) to give the title compound (4.8 g, 77%) as a solid.

δ ¹H-NMR (CDCl₃): 1.64 (s, 2H), 7.20-7.25 (d, 1H), 7.44-7.46 (m, 1H), 8.32-8.36 (d, 1H), 8.52-8.56 (d, 1H), 8.70-8.74 (m, 1H), 9.22-9.26 (m, 1H).

ESI/MS m/e: 217 ([M+H]⁺, C₁₀H₈N₄O₂)

Step b:




3-Bromo-5-nitro-2,3'-bipyridin-6-amine

To a 0°C cooled stirred solution of 5-nitro-2,3'-bipyridin-6-amine (4.8 g, 22.2 mmol) in DMF (50 mL), *N*-bromosuccinimide (4.75 g, 26.7 mmol) was added in portions. After stirring at room temperature for 16h, the solvent was removed under reduced pressure. The crude residue was solved with ethyl acetate and washed with saturated potassium carbonate aqueous solution. The organic layer was washed with brine, dried (MgSO₄) and evaporated. The residue was purified by silica gel flash chromatography (95:5 dichloromethane/methanol) to give the title compound (6.6 g, 100%) as a solid.

δ ¹H-NMR (CDCl₃): 1.60 (s, 2H), 7.40-7.46 (dd, 1H), 8.03-8.09 (m, 1H), 8.67-8.77 (m, 2H), 8.93-9.02 (m, 1H).

ESI/MS m/e: 295, 297 ([M]⁺, [M+2]⁺, C₁₀H₇BrN₄O₂)

Step c:




3''-Fluoro-5'-nitro-3,2':3',4''-terpyridin-6'-amine

An oven dried resealable Schlenk tube was charged with 3-bromo-5-nitro-2,3'-bipyridin-6-amine (4.51 g, 15.3 mmol), 3-fluoro-4-(tributylstannyl)pyridine (11.8 g, 30.6 mmol) and dimethylformamide (150 mL). The Schlenk tube was subjected to three cycles of evacuation-backfilling with argon, and bis(triphenylphosphino)-palladium (II) chloride (1.1 g, 1.53 mmol) and copper (I) iodide (291 mg, 1.53 mmol) were added. After three new cycles of evacuation-backfilling with argon, the Schlenk tube was capped and placed in a 160°C oil bath. After 3h, the solvent was evaporated and the crude residue was treated with 2N hydrogen chloride (130 mL) aqueous solution for 45 minutes. The aqueous solution was washed with ethyl acetate and then neutralised with 6N sodium hydroxide aqueous solution. The solution was extracted with ethyl acetate, dried (MgSO₄) and evaporated. The residue was purified by silica gel flash chromatography (95:5 dichloromethane/methanol) to give the title compound (2.39 g, 51%) as a solid.

δ ¹H-NMR (CDCl₃): 7.32-7.39 (m, 1H), 7.47-7.53 (dd, 1H), 7.66-7.72 (m, 1H), 8.43-8.45 (m, 2H), 8.48-8.50 (dd, 1H), 8.52-8.57 (m, 2H).

ESI/MS m/e: 312 ([M+H]⁺, C₁₅H₁₀FN₅O₂)

Step d:



3''-Fluoro-3,2':3',4''-terpyridine-5',6'-diamine

A suspension of 3''-fluoro-5'-nitro-3,2':3',4''-terpyridin-6'-amine (2.25 g, 7.23 mmol) and 10% palladium on carbon (0.4 g) in a mixture of THF/ ethanol 40:60 (100 mL) was stirred under hydrogen atmosphere. After 3h, the mixture was filtered through Celite® and the filter cake was washed with ethanol. The combined filtrate and washings were evaporated to give the title compound as a solid (2.01 g, 99%).


δ ¹H-NMR (CDCl₃): 5.10 (s, 2H), 5.95 (s, 2H), 6.75 (s, 1H), 7.18-7.30 (m, 2H), 7.49-7.55 (m, 1H), 8.29-8.31 (m, 1H), 8.32-8.34 (m, 1H), 8.35-8.38 (m, 1H), 8.40 (m, 1H).

ESI/MS m/e: 281 ([M+H]⁺, C₁₅H₁₂FN₅)

Intermediate 2:

3,2':3',4''-Terpyridine-5',6'-diamine


Step a:

**5'-Nitro-3,2':3',4''-terpyridin-6'-amine**

Obtained (220 mg, 22%) from 3-bromo-5-nitro-2,3'-bipyridin-6-amine (**Intermediate 1-Step b**, 1.0 g, 3.4 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (764 mg, 3.73 mmol) following the same procedure described in **Intermediate 1**, step a.


δ ^1H NMR (DMSO- d_6): 7.17 (d, 1H), 7.35 (dd, 1H), 7.68-7.40 (m, 3H), 7.82 (d, 1H), 8.22 (broad s, 1H), 8.50-8.40 (m, 2H), 8.53 (broad d, 1H), 8.69 (broad s, 1H).

ESI/MS m/e: 294 ($[\text{M}+\text{H}]^+$, $\text{C}_{15}\text{H}_{11}\text{N}_5\text{O}_2$).

Step b:**3,2':3',4''-Terpyridine-5',6'-diamine**

Obtained (148 mg, 75%) from 5'-nitro-3,2':3',4''-terpyridin-6'-amine (220 mg, 0.75 mmol) following the same protocol described in **Intermediate 1**, step d.


ESI/MS m/e: 264 ($[\text{M}+\text{H}]^+$, $\text{C}_{15}\text{H}_{13}\text{N}_5$).

Intermediate 3:**3''-Chloro-3,2':3',4''-terpyridine-5',6'-diamine****Step a:****2,3'-Dichloro-5-nitro-3,4'-bipyridin-6-amine**

Following the same procedure as in **Intermediate 1** (step a), but using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-chloropyridine, 6-chloro-5-iodo-3-nitropyridin-2-amine (**Intermediate 5 - step a**) was transformed into the title compound as a white solid (205 mg, 22%).


δ ^1H NMR (CDCl_3): 7.28 (d, 1H), 8.39 (s, 1H), 8.61 (d, 1H), 8.75 (s, 1H).

ESI/MS m/e: 286 ($[\text{M}+\text{H}]^+$, $\text{C}_{10}\text{H}_6\text{Cl}_2\text{N}_4\text{O}_2$).

Step b:**3''-Chloro-5'-nitro-3,2':3',4''-terpyridin-6'-amine**

Following the same procedure as in Intermediate 1 (step a), 2,3'-dichloro-5-nitro-3,4'-
 5 bipyrindin-6-amine afforded the title compound as a brownish solid (127 mg, 54%).

ESI/MS m/e: 328 ([M+H]⁺, C₁₅H₁₀ClN₅O₂).


Step c:**3''-Chloro-3,2':3',4''-terpyridine-5',6'-diamine**

10 3''-chloro-5'-nitro-3,2':3',4''-terpyridin-6'-amine (127 mg, 0.39 mmol) was dissolved in EtOH (4.0 mL) and conc. HCl (245 µL). Iron metal (109 mg, 1.09 mmol) was added to the suspension and the mixture was heated to 70 °C for 1 h. The suspension was then filtered through Celite® and the solvent removed *in vacuo*. NaHCO₃ (20 mL of a 4% w/w aqueous solution) was added to the residue and the aqueous phase was extracted with AcOEt (3 x
 15 20 mL). The organic layer was dried, filtered and concentrated to dryness to yield the title compound (52 mg, 45%), which was used without further purification.

ESI/MS m/e: 298 ([M+H]⁺, C₁₅H₁₂ClN₅).

Intermediate 4:

20 **4,2':3',4''-Terpyridine-5',6'-diamine**


Step a:**5-Nitro-2,4'-bipyridin-6-amine**

Obtained (0.240g, 96% of yield) from 6-chloro-3-nitropyridin-2-amine (0.2 g, 1.15 mmol)
 25 and 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine (0.308 g, 1.50 mmol) following the procedure described in Intermediate 1, step a.

δ $^1\text{H-NMR}$ (CDCl_3): 7.23-7.27 (d, 1H), 7.87-7.90 (m, 2H), 8.54-8.58 (d, 1H), 8.76-8.79 (m, 2H).

ESI/MS m/e : 217 ($[\text{M}+\text{H}]^+$, $\text{C}_{10}\text{H}_8\text{N}_4\text{O}_2$)

Step b:




5

3-Bromo-5-nitro-2,4'-bipyridin-6-amine

Obtained (0.246 g, 76% of yield) from 5-nitro-2,4'-bipyridin-6-amine (0.240 g, 1.11 mmol) following the procedure described in Intermediate 1, step b.

ESI/MS m/e : 295, 297 ($[\text{M}]^+$, $[\text{M}+2]^+$, $\text{C}_{10}\text{H}_7\text{BrN}_4\text{O}_2$)

10 Step c:




5'-Nitro-4,2':3',4''-terpyridin-6'-amine

Obtained (0.144 g, 60% of yield) from 3-bromo-5-nitro-2,4'-bipyridin-6-amine (0.240 g, 0.813 mmol) and 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine (0.250 g, 1.220 mmol) following the procedure described in Intermediate 1, step c.

15

ESI/MS m/e : 294 ($[\text{M}+\text{H}]^+$, $\text{C}_{15}\text{H}_{11}\text{N}_5\text{O}_2$)

Step d:




4,2':3',4''-Terpyridine-5',6'-diamine

To a solution of 5'-nitro-4,2':3',4''-terpyridin-6'-amine (0.144 g, 0.490 mmol) in ethanol (5 mL), 0.300 mL of hydrogen chloride and 0.140 g (2.45 mmol) of iron were added. The mixture was heated at 90°C for 2h and the solvent was evaporated. The crude mixture was extracted between ethyl acetate and water. The organic layer was dried (MgSO_4) and the solvent evaporated to give the title compound (0.120 g, 93% of yield).

25

ESI/MS m/e : 264 ($[\text{M}+\text{H}]^+$, $\text{C}_{15}\text{H}_{13}\text{N}_5$)


Intermediate 5:**3-Fluoro-4,2':3',4''-terpyridine-5',6'-diamine****Step a:****5 6-Chloro-5-iodo-3-nitropyridin-2-amine**

To a suspension of 6-chloro-3-nitropyridin-2-amine (6.3 g, 36.3 mmol) in ethanol (110 mL), 9.2 g (36.3 mmol) of iodine and 11.32 g (36.3 mmol) of silver sulphate were added. The crude mixture was stirred at room temperature overnight and the precipitate formed was filtered off. The solid isolated was purified by flash chromatography (1:1 hexane/ethyl

10 acetate) to give the title compound (9.74 g, 88% of yield).

δ $^1\text{H-NMR}$ (CDCl_3): 1.56 (s, 2H), 8.76 (s, 1H).


ESI/MS m/e : 300 ($[\text{M}+\text{H}]^+$, $\text{C}_5\text{H}_3\text{ClIN}_3\text{O}_2$)

Step b:**15 2-Chloro-5-nitro-3,4'-bipyridin-6-amine**

Obtained (0.666 g, 80% of yield) from 6-chloro-5-iodo-3-nitropyridin-2-amine (1 g, 3.34 mmol) and 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine (0.754 g, 3.67 mmol) following the procedure described in Intermediate 1, step a.

ESI/MS m/e : 251 ($[\text{M}+\text{H}]^+$, $\text{C}_{10}\text{H}_7\text{ClN}_4\text{O}_2$)

20

Step c:**3-Fluoro-5'-nitro-4,2':3',4''-terpyridin-6'-amine**


Obtained (0.214 g, 69% of yield) from 2-chloro-5-nitro-3,4'-bipyridin-6-amine (0.250 g, 1 mmol) and 3-fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine (0.445 g, 2 mmol) following the procedure described in Intermediate 1, step a.

25

δ $^1\text{H-NMR}$ (CDCl_3): 1.24 (s, 2H), 7.04-7.07 (m, 2H), 7.39-7.45 (m, 2H), 8.37 (s, 1H), 8.51-8.57 (m, 3H).

ESI/MS m/e: 312 ($[M+H]^+$, $C_{15}H_{10}FN_5O_2$)

Step d:



3-Fluoro-4,2':3',4''-terpyridine-5',6'-diamine

- 5 Obtained (0.183 g, 94% of yield) from 3-fluoro-5'-nitro-4,2':3',4''-terpyridin-6'-amine (0.215 g, 0.69 mmol) following the procedure described in Intermediate 1, step d.

δ 1H -NMR ($CDCl_3$): 1.26 (s, 4H), 7.00-7.05 (m, 3H), 7.37-7.43 (m, 1H), 8.27 (s, 1H), 8.40-8.48 (m, 3H).


ESI/MS m/e: 282 ($[M+H]^+$, $C_{15}H_{12}FN_5$)

10

Intermediate 6:

3-Chloro-4,2':3',4''-terpyridine-5',6'-diamine

Step a:



- 15 **3'-Chloro-5-nitro-2,4'-bipyridin-6-amine**


Following the same procedure as in Intermediate 1 (step a), but using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-chloropyridine, 6-chloro-3-nitropyridin-2-amine was transformed into the title compound as a white solid (2.14 g, 99%).

δ 1H NMR ($CDCl_3$): 7.15 (d, 1H), 7.52 (d, 1H), 8.55 (d, 1H), 8.62 (d, 1H), 8.73 (s, 1H).

20

ESI/MS m/e: 251 ($[M+H]^+$, $C_{10}H_7ClN_4O_2$).

Step b:




3-Bromo-3'-chloro-5-nitro-2,4'-bipyridin-6-amine

- 25 Following the same procedure as in Intermediate 1 (step b) 3'-chloro-5-nitro-2,4'-bipyridin-6-amine afforded the title compound as a brownish solid (2.04 g, 93%).

δ 1H NMR ($CDCl_3$): 7.25 (d, 1H), 8.64 (d, 1H), 8.73 (s, 1H), 8.74 (d, 1H).


ESI/MS m/e: 328,330 ($[M]^+$, $[M+2]^+$, $C_{10}H_6BrClN_4O_2$).

Step c:**3-Chloro-5'-nitro-4,2':3',4''-terpyridin-6'-amine**

Following the same procedure as in Intermediate 1 (step a), but using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, 3-bromo-3'-chloro-5-nitro-2,4'-bipyridin-6-amine was converted to the title compound as yellowish solid (0.84 g, 85%).

δ ^1H NMR (CDCl_3): 7.03 (broad d, 2H), 7.25 (d, 1H), 8.51 (broad d, 2H), 8.55 (d, 1H), 8.57 (s, 1H), 8.59 (s, 1H).


ESI/MS m/e : 328 ($[\text{M}+\text{H}]^+$, $\text{C}_{15}\text{H}_{10}\text{ClN}_5\text{O}_2$).

10 **Step d:****3-Chloro-4,2':3',4''-terpyridine-5',6'-diamine**

Following the same procedure as in Intermediate 1 (step d), 3-chloro-5'-nitro-4,2':3',4''-terpyridin-6'-amine gave the title compound as white solid (0.78 g, >99%).


15 δ ^1H NMR (DMSO): 5.14 (broad s, 2H), 5.94 (broad s, 2H), 6.83 (s, 1H), 6.95 (broad d, 2H), 7.32 (d, 1H), 8.33 (broad d, 2H), 8.42 (d, 1H), 8.46 (s, 1H).

ESI/MS m/e : 298 ($[\text{M}+\text{H}]^+$, $\text{C}_{15}\text{H}_{12}\text{ClN}_5$).

Intermediate 7:20 **3''-Chloro-4,2':3',4''-terpyridine-5',6'-diamine****Step a:****2,3'-Dichloro-5-nitro-3,4'-bipyridin-6-amine**

Obtained (0.118 g, 41% of yield) from 6-chloro-5-iodo-3-nitropyridin-2-amine (0.3 g, 1 mmol) and 3-chloro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine (0.311 g, 1.3 mmol) following the procedure described in Intermediate 3, step a.


ESI/MS m/e : 285 ($[\text{M}+\text{H}]^+$, $\text{C}_{10}\text{H}_6\text{Cl}_2\text{N}_4\text{O}_2$)

Step b:**3''-Chloro-5'-nitro-4,2':3',4''-terpyridin-6'-amine**

Obtained (0.130 g, 99% of yield) from 2,3'-dichloro-5-nitro-3,4'-bipyridin-6-amine (0.120 g, 0.42 mmol) and 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine (0.130 g, 0.63 mmol) following the procedure described in Intermediate 1, step a.


δ $^1\text{H-NMR}$ (CDCl_3): 1.24 (s, 2H), 7.12-7.23 (m, 3H), 7.40-7.64 (m, 1H), 8.48-8.57 (m, 2H), 8.61 (s, 1H).

ESI/MS m/e: 328 ($[\text{M}+\text{H}]^+$, $\text{C}_{15}\text{H}_{10}\text{ClN}_5\text{O}_2$)

10 **Step c:****3''-Chloro-4,2':3',4''-terpyridine-5',6'-diamine**

Obtained (0.082 g, 62% of yield) from 3''-chloro-5'-nitro-4,2':3',4''-terpyridin-6'-amine (0.145 g, 0.443 mmol) following the procedure described in Intermediate 4, step d.


15 ESI/MS m/e: 298 ($[\text{M}+\text{H}]^+$, $\text{C}_{15}\text{H}_{12}\text{ClN}_5$)

Intermediate 8:**3-Chloro-3''-fluoro-4,2':3',4''-terpyridine-5',6'-diamine**


20 Obtained as a white solid (24%) from 3-bromo-3'-chloro-5-nitro-2,4'-bipyridin-6-amine (Intermediate 6-step b) and 3-fluoro-4-(tributylstannyl)pyridine, following the same procedure as in Intermediate 1 (step c).

ESI/MS m/e: 316 ($[\text{M}+\text{H}]^+$, $\text{C}_{15}\text{H}_{11}\text{ClFN}_5$).

25 **Intermediate 9:**

3,3''-Dichloro-4,2':3',4''-terpyridine-5',6'-diamine**Step a:****3,3''-Dichloro-5'-nitro-4,2':3',4''-terpyridin-6'-amine**

- 5 Obtained (0.034 g, 10% of yield) from 6-chloro-5-iodo-3-nitropyridin-2-amine (0.3 g, 1 mmol) and 3-chloro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine (0.311 g, 1.3 mmol) following the procedure described in Intermediate 1, step a.

ESI/MS m/e: 362 ([M+H]⁺, C₁₅H₉Cl₂N₅O₂)**Step b:**


10

3,3''-Dichloro-4,2':3',4''-terpyridine-5',6'-diamine

Obtained (0.029 g, 72% of yield) from 3,3''-dichloro-5'-nitro-4,2':3',4''-terpyridin-6'-amine (0.045 g, 0.123 mmol) following the procedure described in Intermediate 4, step d.

ESI/MS m/e: 332 ([M+H]⁺, C₁₅H₁₁Cl₂N₅)

15

Intermediate 10:**2-(1,3-Oxazol-2-yl)-3,4'-bipyridine-5,6-diamine****Step a:****20 6-Chloro-2-methoxy-3-nitropyridine**


- Methanol (3.3 g, 103 mmol) in xylene (100 mL) was added dropwise to a stirred suspension of sodium hydride (60% in mineral oil, 2.72 g, 113 mmol) in xylene (300 mL) at 0 °C under an argon atmosphere. After 20 minutes, 2,6-dichloro-3-nitropyridine (20.0 g, 103 mmol) in xylene (300 mL) was added dropwise then the reaction was warmed to ambient temperature and stirred overnight. Water (200 mL) was then added and the two phases were separated. The organic layer was washed with water and brine, dried

25

(MgSO₄) and evaporated. The residue was purified by flash chromatography (10:1 hexanes/ethyl acetate) to give the title compound (15.3 g, 78%) as a white solid.

δ ¹H-NMR (CDCl₃): 4.10 (s, 3H), 7.05 (d, 1H), 8.28 (d, 1H).

5 **Step b:**



2-Methoxy-3-nitro-6-(1,3-oxazol-2-yl)pyridine


An oven-dried resealable Schlenk tube was charged with 6-chloro-2-methoxy-3-nitropyridine (0.50 g, 2.6 mmol), 2-tributylstannanyloxazole (1.20 g, 3.4 mmol) and 1,4-dioxane (10 mL) and then subjected to several cycles of evacuation-backfilling with argon. Tetrakis(triphenylphosphine)palladium (0.18 g, 0.16 mmol) was then added and, after three new cycles of evacuation-backfilling with argon, the Schlenk tube was sealed and the mixture was stirred and heated in an oil bath to 110 °C. After stirring overnight, water and ethyl acetate were added and the organic layer was washed with water, dried (MgSO₄) and evaporated. The residue was purified by flash chromatography (2:1 hexanes/ethyl acetate) to give the title compound (0.38 g, 67%) as a yellow solid.

δ ¹H-NMR (CDCl₃): 4.24 (s, 3H), 7.38 (s, 1H), 7.84 (d, 1H), 7.87 (s, 1H), 8.40 (d, 1H).

ESI/MS m/e: 222 ([M+H]⁺, C₉H₇N₃O₄)

20

Step c:




3-Nitro-6-(1,3-oxazol-2-yl)pyridin-2-amine

A suspension of 2-methoxy-3-nitro-6-(1,3-oxazol-2-yl)pyridine (0.187 g, 0.85 mmol) in aqueous ammonia (32%, 5 mL) was heated in a sealed tube to 100 °C with stirring. After 2.5 hours the mixture was cooled and the precipitate was filtered and washed with water and then dried in vacuo to give the title compound (0.134 g, 77%) as a yellow solid.

δ ¹H-NMR (DMSO-d₆): 7.41 (d, 1H), 7.53 (s, 1H), 8.14 (s, 2H), 8.38 (s, 1H), 8.53 (d, 1H).

30


ESI/MS m/e: 207 ([M+H]⁺, C₈H₆N₄O₃)

Step d:**5-Bromo-3-nitro-6-(1,3-oxazol-2-yl)pyridin-2-amine**

To a stirred solution of 3-nitro-6-(1,3-oxazol-2-yl)pyridin-2-amine (0.127 g, 0.62 mmol) in dimethylformamide (3 mL) at 0 °C was added *N*-bromosuccinimide (0.115 g, 0.65 mmol) and the mixture was warmed to room temperature. After 3 days, further *N*-bromosuccinimide (0.058 g, 0.33 mmol) was added and stirring was continued for 3 hours. The solution was poured into water and the precipitate was filtered, washed with water and dried to give the title compound (0.18 g, 70%) as a yellow solid.

10 δ ¹H NMR (DMSO-*d*₆): 7.56 (s, 1H), 8.19 (s, 2H), 8.41 (s, 1H), 8.68 (s, 1H).

ESI/MS *m/e*: 285/287 ([*M*+*H*]⁺, C₈H₅BrN₄O₃)

Step e:**15 5-Nitro-2-(1,3-oxazol-2-yl)-3,4'-bipyridin-6-amine**


An oven-dried resealable Schlenk tube was charged with 5-bromo-3-nitro-6-(1,3-oxazol-2-yl)pyridin-2-amine (0.141 g, 0.49 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (0.203 g, 0.99 mmol), dioxane (5 mL) and a 2M aqueous solution of cesium carbonate (0.74 mL, 1.48 mmol). The Schlenk tube was subjected to three cycles of evacuation-backfilling with argon, and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex [PdCl₂dppf.DCM] (0.024 g, 0.03 mmol) was added. After three new cycles of evacuation-backfilling with argon, the Schlenk tube was sealed and the mixture was stirred and heated in an oil bath to 95 °C. After 20 hours, the mixture was cooled and partitioned between 2M aqueous hydrochloric acid and ethyl acetate. The aqueous phase was filtered through Celite® and the pH was adjusted to 5-6 with solid sodium hydroxide. The suspension was cooled in an ice bath and the precipitate was filtered, washed with water and dried to give the title compound (0.090 g, 65%) as a yellow solid.

25 δ ¹H-NMR (DMSO-*d*₆): 7.24 (d, 2H), 7.33 (s, 1H), 8.24 (s, 1H), 8.29 (s, 2H), 8.43 (s, 1H), 8.52 (d, 2H).

30

ESI/MS m/e: 284 ([M+H]⁺, C₁₃H₉N₅O₃)

Step f:



5 2-(1,3-Oxazol-2-yl)-3,4'-bipyridine-5,6-diamine

A suspension of 5-nitro-2-(1,3-oxazol-2-yl)-3,4'-bipyridin-6-amine (0.089 g, 0.31 mmol) and palladium on carbon (10%, 20 mg) in ethanol (15 mL) was placed under a hydrogen atmosphere (balloon) and stirred at room temperature. After 3 hours, the mixture was filtered through Celite® and the filtrate was evaporated. Trituration with diethyl ether gave
 10 the title compound (0.077 g, 97%) as a pale orange solid.


δ ¹H-NMR (CDCl₃): 6.87 (s, 1H), 7.13 (m, 3H), 7.49 (s, 1H), 8.56 (d, 2H).

ESI/MS m/e: 254 ([M+H]⁺, C₁₃H₁₁N₅O)

Intermediate 11:

15 3'-Fluoro-2-(1,3-oxazol-2-yl)-3,4'-bipyridine-5,6-diamine

Step a:



6-Chloro-N,N-bis(4-methoxybenzyl)-3-nitropyridin-2-amine


20 A solution of N,N-bis(4-methoxybenzyl)amine (7.79 g, 30.3 mmol) and triethylamine (2.89 g, 28.6 mmol) in chloroform (20 mL) was added dropwise over 20 minutes to a cold (ice-bath), stirred solution of 2,6-dichloro-3-nitropyridine (5.0 g, 26.0 mmol) in chloroform (25 mL). The mixture was warmed to room temperature and stirred overnight. The solvent was evaporated and the mixture was partitioned between ethyl acetate and water. The
 25 organic layer was washed with brine, dried (MgSO₄) and evaporated to give an oil. The mixture was taken up in dichloromethane (120 mL) and polymer-supported isocyanate resin (1.6 mmol/g, 8.0 g) was added and the mixture was shaken at room temperature for

2 days. The mixture was filtered and the filtrate was evaporated to give the title compound (10.7 g, 100%) as a bright yellow oil.

δ $^1\text{H-NMR}$ (CDCl_3): 3.78 (s, 6H), 4.51 (s, 4H), 6.68 (d, 2H), 6.80 (d, 4H), 8.23 (d, 4H), 8.02 (d, 1H).

5 ESI/MS m/e : 414 ($[\text{M}+\text{H}]^+$, $\text{C}_{21}\text{H}_{20}\text{ClN}_3\text{O}_4$)

Step b:



2-N,N-bis(4-methoxybenzyl)-3-nitro-6-(1,3-oxazol-2-yl)pyridine


10 Obtained (79%) from 6-chloro-N,N-bis(4-methoxybenzyl)-3-nitropyridin-2-amine and 2-tributylstannanyloxazole, following the procedure described in Preparation 10, step b.

δ $^1\text{H-NMR}$ (CDCl_3): 3.79 (s, 6H), 4.60 (s, 4H), 6.80 (d, 4H), 7.10 (d, 4H), 7.34 (d, 1H), 7.55 (d, 1H), 7.82 (s, 1H), 8.20 (d, 1H).

ESI/MS m/e : 447 ($[\text{M}+\text{H}]^+$, $\text{C}_{24}\text{H}_{22}\text{N}_4\text{O}_5$)

15

Step c:




4-Bromo-2-N,N-bis(4-methoxybenzyl)-3-nitro-6-(1,3-oxazol-2-yl)pyridine

Obtained (52%) from 2-N,N-bis(4-methoxybenzyl)-3-nitro-6-(1,3-oxazol-2-yl)pyridine and 20 N-bromosuccinimide, following the procedure described in Preparation 10, step d.

δ $^1\text{H-NMR}$ ($\text{DMSO}-d_6$): 3.69 (s, 6H), 4.59 (s, 4H), 6.83 (d, 4H), 7.12 (d, 4H), 7.58 (s, 1H), 8.42 (s, 1H), 8.51 (s, 1H).

ESI/MS m/e : 525/527 ($[\text{M}+\text{H}]^+$, $\text{C}_{24}\text{H}_{21}\text{BrN}_4\text{O}_5$)

Step d:




2-N,N-bis(4-methoxybenzyl)-4-(3-fluoropyridin-4-yl)-3-nitro-6-(1,3-oxazol-2-yl)pyridine

An oven-dried resealable Schlenk tube was charged with 4-Bromo-2-N,N-bis(4-methoxybenzyl)-3-nitro-6-(1,3-oxazol-2-yl)pyridine (5.47 g, 10.4 mmol), 3-fluoro-4-(tributylstannyl)pyridine (5.22 g, 13.5 mmol) and dimethylformamide (82 mL). The Schlenk tube was subjected to three cycles of evacuation-backfilling with argon, and bis(triphenylphosphino)-palladium (II) chloride (0.365 g, 0.52 mmol) and copper (I) iodide (0.198 g, 1.04 mmol) were added. After three new cycles of evacuation-backfilling with argon, the Schlenk tube was sealed and the mixture was stirred and heated to 160 °C in an oil bath. After 20 hours, the mixture was cooled and the solvent evaporated. The residue was taken up in a mixture of methanol and ethyl acetate, filtered through a plug of Celite® and evaporated. Purification by flash chromatography (6:1 hexanes/ethyl acetate to hexanes/ethyl acetate) provided the title compound (4.07 g, 72%) as a solid.

ESI/MS m/e: 542 ([M+H]⁺, C₂₉H₂₄FN₅O₅)

Step e:



3'-Fluoro-5-nitro-2-(1,3-oxazol-2-yl)-3,4'-bipyridin-6-amine

20


A solution of 2-N,N-bis(4-methoxybenzyl)-4-(3-fluoropyridin-4-yl)-3-nitro-6-(1,3-oxazol-2-yl)pyridine (0.15 g, 0.37 mmol) in dichloromethane (2 mL) and trifluoroacetic acid (2 mL) was stirred at ambient temperature overnight. The solvent was evaporated and then the mixture was neutralized with 4% aqueous sodium hydrogen carbonate solution. The solid that formed was extracted with ethyl acetate and the organic layer was washed with water, brine, dried (MgSO₄) and evaporated to give the title compound (0.11 g, 67%) as a yellow solid.

25

δ $^1\text{H-NMR}$ (CDCl_3): 7.21 (s, 1H), 7.30 (m, 1H), 7.71 (s, 1H), 8.51 (m, 3H).

ESI/MS m/e : 302 ($[\text{M}+\text{H}]^+$, $\text{C}_{13}\text{H}_8\text{FN}_5\text{O}_3$)

Step f:



5

3'-Fluoro-2-(1,3-oxazol-2-yl)-3,4'-bipyridine-5,6-diamine

Obtained (93%) from 3'-fluoro-5-nitro-2-(1,3-oxazol-2-yl)-3,4'-bipyridin-6-amine by hydrogenation over palladium on carbon following the procedure described in Preparation 10, step f.


10 δ $^1\text{H-NMR}$ ($\text{DMSO}-d_6$): 5.42 (s, 2H), 6.07 (s, 2H), 6.65 (s, 1H), 7.05 (s, 2H), 7.30 (m, 1H), 7.96 (s, 1H), 8.39 (m, 2H).

ESI/MS m/e : 272 ($[\text{M}+\text{H}]^+$, $\text{C}_{13}\text{H}_{10}\text{FN}_5\text{O}$)

Intermediate 12

15 **2-(1,3-Oxazol-5-yl)-3,4'-bipyridine-5,6-diamine**

Step a:



20


2-Triisopropylsilyloxazole

n-BuLi (1.6M in hexanes, 76 mL, 190 mmol) was added dropwise over 30 minutes to a stirred solution of oxazole (12.0 g, 174 mmol) in diethyl ether (400 mL) at -78°C under argon. The solution was allowed to stir for 60 minutes at -78°C and then triisopropylsilyl triflate (46.3 mL, 172 mmol) was added dropwise over 30 minutes. The reaction mixture was slowly warmed up to room temperature and stirred overnight. The mixture was concentrated in vacuo and the residue was taken up in hexanes and filtered through a pad of silica gel eluting with 8:1 hexanes/ethyl acetate. Concentration gave the title compound (36.0 g, 93%) as a colourless oil.

δ $^1\text{H-NMR}$ (CDCl_3): 1.12 (d, 18H), 1.37 (m, 3H), 7.20 (m, 1H), 7.81 (d, 1H).

Step b:

5-Tributylstannanyl-2-triisopropylsilanyl-oxazole




5

tert-BuLi (1.7M in *n*-pentane, 8.4 mL, 14.3 mmol) was added dropwise over (approximately) 30 minutes to a stirred solution of 2-triisopropylsilyloxazole (3g, 13 mmol) in tetrahydrofuran (75 mL) at -78°C under argon. The solution was allowed to stir for 20 minutes at -78°C and tributyltin chloride (5.2 mL, 19.5 mmol) was then added over 20 minutes. The reaction mixture was warmed to room temperature and stirred for an additional 16 hours. The reaction was diluted with ethyl acetate, washed with water and the organic layer was dried (MgSO_4) and concentrated under reduced pressure. The crude product was dissolved in *n*-pentane, filtered through Celite® and the solvent evaporated to give the title compound in quantitative yield as a pale-yellow oily residue, which was used without further purification in the next step.

15

δ $^1\text{H-NMR}$ (CDCl_3): 1.12 (d, 18H), 1.38 (m, 3H), 1.42 (d, 9H), 1.52-1.95 (m, 18H) 7.22 (s, 1H).

20 **Step c:**




3-Nitro-6-(2-triisopropylsilanyl-1,3-oxazol-5-yl)pyridin-2-amine

Obtained (80%) from 6-bromo-3-nitropyridin-2-amine and 5-tributylstannanyl-2-triisopropylsilyloxazole, following the procedure described in Preparation 10, step b.

25 δ $^1\text{H-NMR}$ (CDCl_3): 1.17 (d, 18H), 1.43 (m, 3H), 7.11 (d, 1H), 7.85 (s, 1H), 8.48 (d, 1H).

ESI/MS *m/e*: 363 ($[\text{M}+\text{H}]^+$, $\text{C}_{17}\text{H}_{26}\text{N}_4\text{O}_3\text{Si}$)

Step c: (alternative method)




3-Nitro-6-(2-triisopropylsilyl-1,3-oxazol-5-yl)pyridin-2-amine

Obtained (67%) from 6-chloro-3-nitropyridin-2-amine and 5-tributylstannanyl-2-triisopropylsilyloxazole, following the procedure described in Preparation 10, step b.

5

Step d:



5-Bromo-3-nitro-6-(2-triisopropylsilyl-1,3-oxazol-5-yl)pyridin-2-amine


Obtained (88%) from 3-nitro-6-(2-triisopropylsilyl-1,3-oxazol-5-yl)pyridin-2-amine and *N*-bromosuccinimide, following the procedure described in Preparation 10, step d.

10

δ $^1\text{H-NMR}$ (CDCl_3): 1.17 (d, 18H), 1.45 (m, 3H), 8.15 (s, 1H), 8.68 (s, 1H).

ESI/MS m/e : 441/443 ($[\text{M}+\text{H}]^+$, $\text{C}_{17}\text{H}_{26}\text{BrN}_4\text{O}_3\text{Si}$)

Step e:



15

5-Nitro-2-(1,3-oxazol-5-yl)-3,4'-bipyridin-6-amine


Obtained (74%) from 5-bromo-3-nitro-6-(2-triisopropylsilyl-1,3-oxazol-5-yl)pyridin-2-amine and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine following the procedure described in Preparation 10, step e.

20

δ $^1\text{H-NMR}$ (CDCl_3): 7.15 (s, 1H), 7.38 (d, 2H), 8.20 (s, 1H), 8.32 (s, 1H), 8.45 (s, 1H), 8.62 (d, 2H).

ESI/MS m/e : 284 ($[\text{M}+\text{H}]^+$, $\text{C}_{13}\text{H}_9\text{N}_5\text{O}_3$)

Step f:



2-(1,3-Oxazol-5-yl)-3,4'-bipyridine-5,6-diamine


Obtained (82%) from 5-nitro-2-(1,3-oxazol-5-yl)-3,4'-bipyridin-6-amine by hydrogenation over palladium on carbon following the procedure described in Preparation 10, step f.

- 5 δ $^1\text{H-NMR}$ (DMSO- d_6): 5.26 (s, 2H), 5.94 (s, 2H), 6.67 (s, 1H), 6.79 (s, 1H), 7.16 (d, 2H), 8.12 (s, 1H), 8.52 (m, 2H).
ESI/MS m/e: 254 ($[\text{M}+\text{H}]^+$, $\text{C}_{13}\text{H}_{11}\text{N}_5\text{O}$)

Intermediate 13

- 10 **3'-Fluoro-2-(1,3-oxazol-5-yl)-3,4'-bipyridine-5,6-diamine**


Step a:



3'-Fluoro-5-nitro-2-(1,3-oxazol-5-yl)-3,4'-bipyridin-6-amine

- 15 Obtained (18%) from 5-bromo-3-nitro-6-(2-triisopropylsilanyl-1,3-oxazol-5-yl)pyridin-2-amine and 3-fluoro-4-(tributylstannyl)pyridine following the procedure described in Preparation 11, step d.
 δ $^1\text{H-NMR}$ (CDCl_3): 7.30 (m, 1H), 7.38 (s, 1H), 7.81 (s, 1H), 8.40 (s, 1H), 8.52 (m, 2H).
20 ESI/MS m/e: 302 ($[\text{M}+\text{H}]^+$, $\text{C}_{13}\text{H}_8\text{FN}_5\text{O}_3$)

Step b:



3'-Fluoro-2-(1,3-oxazol-5-yl)-3,4'-bipyridine-5,6-diamine


Obtained (89%) from 3'-fluoro-5-nitro-2-(1,3-oxazol-5-yl)-3,4'-bipyridin-6-amine by hydrogenation over palladium on carbon following the procedure described in Preparation 10, step f.

ESI/MS m/e: 272 ([M+H]⁺, C₁₃H₁₀FN₅O)

5

Intermediate 14

Step a:



3'',5''-difluoro-5'-nitro-3,2':3',4''-terpyridin-6'-amine


10 A mixture of 3-bromo-5-nitro-2,3'-bipyridin-6-amine (Intermediate 1, step b, 1 g, 3.39 mmol), 3,5-difluoro-4-tributylstannanylpuridine (1.5 g, 3.71 mmol), bis(triphenylphosphino) palladium (II) chloride (0.24 g, 0.34 mmol) and copper (I) iodide (0.13 g, 0.68 mmol) in dioxane (15 mL) was heated at 150 °C for 6 hours in Biotage Initiator Microwave Synthesizer.

15 The mixture was filtered through Celite® and the filter cake was washed with dioxane. The solvent was evaporated and the crude residue was purified by silica gel flash chromatography (95:5 dichloromethane/methanol) to give the title compound (1.07 g, 95%) as a yellow solid.

ESI/MS m/e: 330 ([M+H]⁺, C₁₅H₉F₂N₅O₂).

20


Step b:



3'',5''-difluoro-3,2':3',4''-terpyridine-5',6'-diamine

25 A suspension of 3'',5''-difluoro-5'-nitro-3,2':3',4''-terpyridin-6'-amine (0.2 g, 0.608 mmol) and 10% palladium on carbon (0.04 g) in a mixture of THF/ ethanol 40:60 (8 mL) was stirred under hydrogen atmosphere at 2.76 bar. After 12h, the mixture was filtered through Celite® and the filter cake was washed with ethanol and THF. The combined filtrate and washings were evaporated to give the title compound as a solid (0.180 g, 99%).

ESI/MS m/e: 300 ([M+H]⁺, C₁₅H₁₁F₂N₅).


EXAMPLES**Example 1**

5

6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one


To a solution of 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 1**, 158 mg, 0.56 mmol) in THF (5 mL) Et₃N (156 μ L, 1.12 mmol) and carbonyldiimidazole (182 mg, 1.12 mmol) were added sequentially. The reaction mixture was heated to reflux for 4 h and then the solvent was removed under reduced pressure. Flash chromatography of the resulting crude oil (CH₂Cl₂/EtOH/aq NH₃ 60:8:1 to 40:8:1) followed by reverse phase chromatography (0% CH₃CN in H₂O to 25% CH₃CN in H₂O) gave the title compound as a white solid (29 mg, 17%).

15 δ ¹H-NMR (DMSO-d₆): 7.27 (dd, 1H), 7.33 (s, 1H), 7.44 (dd, 1H), 7.59 (dt, 1H), 8.37 (d, 1H), 8.42 (m, 3H), 11.18 (s, 1H), 11.70 (s, 1H),
ESI/MS m/e: 308 ([M+H]⁺, C₁₆H₁₀FN₅O).

Example 2**20 Step a:****N-(6'-amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)cyclopropanecarboxamide**



To a solution of 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 1**, 0.2 g, 0.71 mmol) in pyridine (2 mL), 0.071 mL (0.78 mmol) of cyclopropanoylcarbonyl chloride were added. The mixture was heated at 80°C for 4h and the solvent was evaporated. The crude mixture was extracted between ethyl acetate and water, the organic layer was dried (MgSO₄) and evaporated. The residue was purified by silica gel flash chromatography (90:10 dichloromethane/methanol) to give the title compound (0.202 g, 82% of yield).

ESI/MS m/e: 350 ([M+H]⁺, C₁₉H₁₆FN₅O)

Step b:**2-Cyclopropyl-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine**


A solution of *N*-(6'-amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)cyclopropanecarboxamide (0.2 g, 0.58 mmol) in acetic acid (2.5 mL) was heated in a sealed tube at 130°C for 16h. The solvent was evaporated and water (1 mL) was added and the solution was neutralised with 4% sodium bicarbonate aqueous solution and extracted with ethyl acetate. The organic layer was washed with brine, dried (MgSO₄) and evaporated. The residue was purified by silica gel flash chromatography (100:8:1 dichloromethane/methanol/NH₃) to give the title compound (0.024g, 12% of yield).

ESI/MS *m/e*: 332 ([*M*+*H*]⁺, C₁₉H₁₄FN₅)

Example 3 and Example 4**2-Cyclohexyl-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine and 6-(3-fluoropyridin-4-yl)-2-methyl-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine**

The same procedure as in Example 2, but using cyclohexanecarbonyl chloride was followed. Final purification of the residue by flash chromatography (CH₂Cl₂/PrOH 98:2 to 65:35) afforded 2-cyclohexyl-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine (**Example 3**) as a yellowish solid (134 mg, 51%): δ ¹H-NMR (CDCl₃): 1.28-1.66 (m, 4H), 1.71-1.98 (m, 4H), 2.15 (broad d, 2H), 7.36 (ddd, 1H), 7.52 (dd, 1H), 7.82 (dt, 1H), 8.01 (s, 1H), 8.36 (d, 1H), 8.42 (dd, 1H), 8.46 (dd, 1H), 8.51 (broad d, 1H), ESI/MS *m/e*: 374 ([*M*+*H*]⁺, C₂₂H₂₀FN₅), and 6-(3-fluoropyridin-4-yl)-2-methyl-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine (**Example 4**) as a white solid (90 mg, 42%) δ ¹H-NMR (CDCl₃): 2.69 (s, 3H), 7.36 (ddd, 1H), 7.52 (dd, 1H), 7.82 (dt, 1H), 8.02 (s, 1H), 8.36 (d, 1H), 8.41 (dd, 1H), 8.46 (dd, 1H), 8.50 (broad d, 1H). ESI/MS *m/e*: 306 ([*M*+*H*]⁺, C₁₇H₁₂FN₅).

Example 5



2-(4-Fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine


3''-Fluoro-3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 1**, 158 mg, 0.56 mmol), 4-fluorobenzoyl chloride (73.0 μ L, 0.62 mmol) and pyridine (ca. 4 mL) were placed in a sealed tube. The solution was initially heated at 140 °C for 48 h and afterwards, at 160 °C for another 48 h. Then, the reaction mixture was cooled to room temperature, the pyridine was removed *in vacuo*, and the crude oil was purified by flash column chromatography ($\text{CH}_2\text{Cl}_2/\text{EtOH}$, 95:5) affording the title compound as a white solid (141 mg, 65%).

δ ^1H -NMR ($\text{DMSO}-d_6$): 6.89 (t, 1H), 7.06 (t, 2H), 7.26 (dd, 1H), 7.56 (dt, 1H), 7.77 (dd, 1H), 7.82 (s, 1H), 7.96 (dd, 2H), 8.14 (dd, 1H), 8.18 (broad d, 1H), 8.25 (broad s, 1H).

ESI/MS m/e : 386 ($[\text{M}+\text{H}]^+$, $\text{C}_{22}\text{H}_{13}\text{F}_2\text{N}_5$).

Example 6

Step a:




N-(6'-Amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)-4-methoxybenzamide

To a solution of 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 1**, 0.1 g, 0.36 mmol) in pyridine (2 mL), 4-methoxybenzoyl chloride (0.066 g, 0.39 mmol) was added.

The mixture was stirred at room temperature overnight and the solvent was evaporated. Dichloromethane (1.6 mL) and tris-(2-aminoethyl)amine polystyrene (0.180 g, 0.72 mmol) were added and the mixture was stirred at room temperature for 1h. The resin was filtrated and washed twice with dichloromethane. The filtrates were combined and the solvent was evaporated to give the title compound (0.172 g) which was used in the next step without further purification.

ESI/MS m/e : 416 ($[\text{M}+\text{H}]^+$, $\text{C}_{23}\text{H}_{18}\text{FN}_5\text{O}_2$)

Step b:



6-(3-Fluoropyridin-4-yl)-2-(4-methoxyphenyl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine


Obtained (0.039 g, 28% of yield) from *N*-(6'-amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)-4-methoxybenzamide following the procedure described in Example 2, step b.

δ $^1\text{H-NMR}$ (CDCl_3): 3.93 (s, 3H), 7.09-7.14 (d, 2H), 7.08-7.36 (m, 4H), 7.48-7.52 (s, 1H), 8.09 (s, 1H), 8.21-8.25 (d, 2H), 8.42-8.48 (m, 1H), 8.54-8.62 (m, 1H), 9.42-9.46 (m, 1H).

ESI/MS m/e : 398 ($[\text{M}+\text{H}]^+$, $\text{C}_{23}\text{H}_{16}\text{FN}_5\text{O}$)

10

Example 7



***N*-{4-[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-yl]phenyl}-*N,N*-dimethylamine**


Obtained (0.020 g, 14% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.1 g, 0.356 mmol) and 4-(dimethylamino)benzoyl chloride (0.072 g, 0.391 mmol) following the procedure described in Example 6.

δ $^1\text{H-NMR}$ (CDCl_3): 3.10 (s, 6H), 6.81-6.85 (d, 2H), 7.21-7.30 (m, 4H), 7.62-7.66 (m, 1H), 7.99 (s, 1H), 8.04-8.09 (d, 2H), 8.37-8.42 (m, 1H), 8.53-8.55 (m, 1H), 8.65-8.70 (m, 1H).

20

ESI/MS m/e : 411 ($[\text{M}+\text{H}]^+$, $\text{C}_{24}\text{H}_{19}\text{FN}_6$)

Example 8



6-(3-Fluoropyridin-4-yl)-2-(4-*tert*-butylphenyl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine


25

Obtained (0.050 g, 33% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.1 g, 0.356 mmol) and 4-tert-butylbenzoyl chloride (0.072 mL, 0.391 mmol) following the procedure described in Example 6.

5 δ ¹H-NMR (CDCl₃): 1.41 (s, 9H), 7.16-7.37 (m, 2H), 7.46-7.50 (m, 2H), 7.61-7.65 (d, 2H), 8.15 (s, 1H), 8.24-8.28 (d, 2H), 8.43-8.49 (m, 2H), 8.66-8.68 (m, 1H), 9.54 (bs, 1H).

ESI/MS m/e: 424 ([M+H]⁺, C₂₈H₂₂FN₅)

Example 9



10


6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-[4-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridine

Following the same procedure as in Example 2, but using 4-(trifluoromethyl)benzoyl chloride, the title compound was obtained as a white solid (172 mg, 57%).

15 δ ¹H-NMR (CDCl₃): 7.21 (dd, 1H), 7.39 (t, 1H), 7.46 (broad d, 1H), 7.89 (d, 2H), 8.19 (s, 1H), 8.47 (d, 2H), 8.52 (broad s, 2H), 8.67 (broad d, 1H), 8.68 (s, 1H), 9.80 (broad s, 1H).

ESI/MS m/e: 436 ([M+H]⁺, C₂₃H₁₃F₄N₅).

20 Example 10




Methyl 4-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-yl]benzoate

Obtained (0.047 g, 31% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.1 g, 0.356 mmol) and methyl 4-(chlorocarbonyl)benzoate (0.078 g, 0.391 mmol) following the procedure described in Example 6.

25 δ ¹H-NMR (DMSO-d₆): 3.90 (s, 3H), 7.30-7.37 (m, 2H), 7.55-7.60 (m, 2H), 7.68-7.74 (m, 2H), 8.14-8.24 (m, 3H), 8.40-8.51 (m, 4H).

ESI/MS m/e: 426 ([M+H]⁺, C₂₄H₁₆FN₅O₂)


Example 11**4-[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-yl]benzoic acid**

- 5 To a solution of methyl 4-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-yl]benzoate (**Example 10**, 0.041 g, 0.097 mmol) in a mixture of THF/ethanol 1:1 (1.2 mL), 2N sodium hydroxide aqueous solution (0.1 mL) was added. The mixture was heated at 60°C for 3h and then neutralised with 2N hydrogen chloride aqueous solution. The solvent was evaporated and the crude mixture was purified by silica gel flash chromatography
- 10 (78:10:10:2 dichloromethane/ethanol/ethyl acetate/acetic acid) to give the title compound (0.013g, 31% of yield).

δ ¹H-NMR (DMSO-*d*₆): 7.31-7.37 (m, 2H), 7.55-7.60 (m, 2H), 7.68-7.74 (m, 2H),
8.09-8.13 (m, 1H), 8.21 (s, 1H), 8.30-8.35 (d, 2H), 8.47-8.51 (m, 3H).

ESI/MS *m/e*: 412 ([M+H]⁺, C₂₃H₁₄FN₅O₂)

15

Example 12**6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-pyridin-4-yl-3H-imidazo[4,5-b]pyridine**


- Obtained (0.070 g, 53% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine
- 20 (**Intermediate 1**, 0.1 g, 0.356 mmol) and isonicotinoyl chloride (0.070 g, 0.391 mmol) following the procedure described in Example 6.

δ ¹H-NMR (CDCl₃): 7.24-7.34 (m, 3H), 7.65-7.69 (m, 1H), 8.12-8.20 (m, 3H), 8.38-
8.44 (m, 2H), 8.53-8.55 (m, 1H), 8.68-8.70 (m, 1H), 8.79-8.82 (m, 2H)

ESI/MS *m/e*: 369 ([M+H]⁺, C₂₁H₁₃FN₆)

25

Example 13



2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine

Obtained (0.027 g, 18% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.1 g, 0.356 mmol) and 2,3-dihydro-1,4-benzodioxine-6-carbonyl chloride (0.078 g, 0.391 mmol) following the procedure described in Example 6.


δ $^1\text{H-NMR}$ (CDCl_3): 4.37 (s, 4H), 7.05-7.34 (m, 4H), 7.36-7.43 (d, 1H), 7.82-7.87 (m, 2H), 8.10 (s, 1H), 8.42-8.49 (m, 2H), 8.66-8.69 (m, 1H), 9.64 (s, 1H).

ESI/MS m/e : 426 ($[\text{M}+\text{H}]^+$, $\text{C}_{24}\text{H}_{16}\text{FN}_5\text{O}_2$)

10

Example 14

Step a:




***N*-(6'-Amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)-3-fluoro-4-methylbenzamide**

To a solution of 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.2 g, 0.71 mmol) in pyridine (2 mL), 0.071 mL (0.78 mmol) of 3-fluoro-4-methylbenzoyl chloride were added. The mixture was heated at 40°C for 4h and the solvent was evaporated. The crude mixture was extracted between ethyl acetate and water, the organic layer was dried (MgSO_4) and evaporated to give the title compound (0.295 g, 88% of yield) which was used in the next step without further purification.

20

ESI/MS m/e : 418 ($[\text{M}+\text{H}]^+$, $\text{C}_{23}\text{H}_{17}\text{F}_2\text{N}_5\text{O}$)

Step b:




6-(3-Fluoropyridin-4-yl)-2-[3-fluoro-4-(trifluoromethyl)phenyl]-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine

Obtained (0.043 g, 15% of yield) from *N*-(6'-amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)-3-fluoro-4-methylbenzamide following the procedure described in Example 2, step b.

5 δ ¹H-NMR (CDCl₃): 7.19-7.24 (m, 2H), 7.38-7.46 (m, 2H), 7.83-7.91 (t, 1H), 8.21 (s, 1H), 8.22-8.29 (m, 2H), 8.45 (s, 1H), 8.52-8.55 (d, 1H), 8.69-8.71 (d, 1H), 9.89 (s, 1H).

ESI/MS m/e: 454 ([M+H]⁺, C₂₃H₁₂F₅N₅)

10 **Example 15**




2-(2,4-Dichloro-5-fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine

Obtained (0.075 g, 47% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.1 g, 0.356 mmol) and 2,4-dichloro-5-fluorobenzoyl chloride (0.070 g, 0.391 mmol) following the procedure described in Example 6.

ESI/MS m/e: 454 ([M+H]⁺, C₂₂H₁₁Cl₂F₂N₅)

Example 16




20

2-(4-Fluorobenzyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine

Obtained (0.035 g, 25% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.1 g, 0.356 mmol) and (4-fluorophenyl)acetyl chloride (0.054 mL, 0.391 mmol) following the procedure described in Example 6.

25 δ ¹H-NMR (CDCl₃): 4.33 (s, 2H), 7.01-7.09 (m, 2H), 7.25-7.38 (m, 4H), 7.55-7.59 (d, 1H), 8.02 (s, 1H), 8.36-8.42 (m, 3H), 8.46-8.49 (d, 1H), 8.70 (s, 1H).

ESI/MS m/e: 400 ([M+H]⁺, C₂₃H₁₅F₂N₅)


Example 17

2-[1-(4-Chlorophenyl)-1-methylethyl]-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine

- 5 Obtained (0.040 g, 49% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.1 g, 0.356 mmol) and 2-(4-chlorophenyl)-2-methylpropanoyl chloride (0.14 g, 0.651 mmol) following the procedure described in Example 6.

δ $^1\text{H-NMR}$ (CDCl_3): 1.61 (s, 6H), 7.00-7.06 (m, 2H), 7.26-7.38 (m, 4H), 8.08-8.14 (m, 3H), 8.42-8.44 (m, 1H), 8.46-8.48 (d, 2H), 9.30 (s, 1H).

- 10 ESI/MS m/e: 444 ($[\text{M}+\text{H}]^+$, $\text{C}_{25}\text{H}_{19}\text{ClFN}_5$)

Example 18


- 15 **(3,5-Difluorophenyl)[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-yl]methanone**

- To a solution of 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.1 g, 0.79 mmol) in pyridine (2 mL), 0.071 mL (0.78 mmol) of 3,5-difluorobenzoyl chloride were added. The mixture was stirred at room temperature for 16h and the solvent was evaporated. The crude mixture was purified by flash chromatography (95:5
20 dichloromethane/methanol) to give the title compound (0.015g, 10% of yield).

δ $^1\text{H-NMR}$ (CDCl_3): 6.96-7.08 (m, 1H), 7.22-7.35 (m, 3H), 7.75 (s, 1H), 7.82-7.87 (m, 1H), 8.18-8.24 (m, 2H), 8.45-8.47 (m, 2H), 8.56-8.58 (m, 2H).

ESI/MS m/e: 432 ($[\text{M}+\text{H}]^+$, $\text{C}_{23}\text{H}_{12}\text{F}_3\text{N}_5\text{O}$)

- 25 **Example 19**




N-(4-Chlorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-amine

To a solution of 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 1**, 0.050 g, 0.179 mmol) and 1-chloro-4-isothiocyanatobenzene (0.045 g, 0.267 mmol) in ethanol (1 mL), 1,3-diisopropylcarbodiimide (0.042 mL, 0.267 mmol) was added. The mixture was heated at 50°C for 2h. After cooling at room temperature, the solid precipitated was filtered off to give the title compound (0.035 g, 47% of yield).

δ ¹H-NMR (MeOD): 7.34-7.38 (m, 3H), 7.44-7.49 (dd, 1H), 7.67-7.70 (m, 2H), 7.73 (s, 1H), 7.77-7.84 (m, 1H), 8.34-8.48 (m, 5H).

ESI/MS m/e: 417 ([M+H]⁺, C₂₂H₁₄ClFN₆)

Example 20




2-(4-Fluorophenyl)-5-pyridin-3-yl-6-pyridin-4-yl-3H-imidazo[4,5-b]pyridine

A sealed tube containing 3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 2**, 148 mg, 0.56 mmol), 4-fluorobenzaldehyde (57.0 μ L, 0.53 mmol) and dioxane (3 mL) was filled with air and heated to 100 °C for 6 days. Then, the solvent was removed and CH₃CN (2 mL) followed by Yb(OTf)₃ were added, and the reaction mixture was stirred for 4 days at room temperature. Afterwards, the solvent was evaporated *in vacuo* and the residue was purified by flash column chromatography (CH₂Cl₂/EtOH/aq NH₃ 100:8:1) to afford the title compound as a white solid (27 mg, 13%).

δ ¹H-NMR (CDCl₃): 7.14-7.34 (m, 6H), 7.40-7.48 (m, 1H), 8.12 (s, 1H), 8.32 (dd, 2H), 8.60 (d, 2H), 8.62 (s, 1H), 9.58 (broad s, 1H).

ESI/MS m/e: 368 ([M+H]⁺, C₂₂H₁₄FN₅).

Example 21


**6-(3-Chloropyridin-4-yl)-5-pyridin-3-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one**

Following the same protocol as in Example 1, but using 3''-chloro-3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 3**), the title compound was obtained as a white solid (29 mg, 17%).

δ $^1\text{H-NMR}$ (CDCl_3): 7.10-7.16 (m, 4H), 7.50 (dt, 1H), 7.80 (broad s, 1H), 8.44 (d, 1H), 8.49 (dd, 1H), 8.61 (s, 1H), 8.80 (d, 1H).

ESI/MS m/e : 324 ($[\text{M}+\text{H}]^+$, $\text{C}_{16}\text{H}_{10}\text{ClN}_5\text{O}$).


10

Example 22**5,6-Dipyridin-4-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one**

Obtained (0.012 g, 23% of yield) from 4,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 4**, 0.048 g, 0.18 mmol) following the procedure described in Example 1.

15

ESI/MS m/e : 290 ($[\text{M}+\text{H}]^+$, $\text{C}_{16}\text{H}_{11}\text{N}_5\text{O}$)

Example 23**5-(3-Fluoropyridin-4-yl)-6-pyridin-4-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one**


Obtained (0.024 g, 15% of yield) from 3-fluoro-4,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 5**, 0.173 g, 1.06 mmol) following the procedure described in Example 1.

20

ESI/MS m/e : 308 ($[\text{M}+\text{H}]^+$, $\text{C}_{16}\text{H}_{10}\text{FN}_5\text{O}$)

Example 24

25




5-(3-Chloropyridin-4-yl)-6-pyridin-4-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one

Following the same protocol as in Example 1, but using 3-chloro-4,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 6**), the title compound was obtained as a white solid (74 mg, 65%).

δ $^1\text{H-NMR}$ (DMSO- d_6): 7.11 (broad d, 2H), 7.35 (s, 1H), 7.41 (d, 1H), 8.41 (broad d, 2H), 8.47 (d, 1H), 8.54 (s, 1H), 11.24 (broad s, 1H), 11.69 (broad s, 1H).

ESI/MS m/e : 324 ($[\text{M}+\text{H}]^+$, $\text{C}_{18}\text{H}_{10}\text{ClN}_5\text{O}$).

10 Example 25




5-(3-Chloropyridin-4-yl)-2-(4-fluorophenyl)-6-pyridin-4-yl-3H-imidazo[4,5-b]pyridine

Following the same protocol as in Example 5, but using 3-chloro-4,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 6**), the title compound was obtained as a white solid (68 mg, 34%).

δ $^1\text{H-NMR}$ (CDCl_3): 7.15 (d, 2H), 7.23-7.32 (m, 3H), 8.14-8.25 (m, 2H), 8.21 (dd, 1H), 8.49 (m, 1H), 8.51 (d, 2H), 8.58 (s, 1H).

ESI/MS m/e : 402 ($[\text{M}+\text{H}]^+$, $\text{C}_{22}\text{H}_{13}\text{ClFN}_5$).

20 Example 26



6-(3-Chloropyridin-4-yl)-5-pyridin-4-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one


Obtained (0.021 g, 23% of yield) from 3'-chloro-4,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 7**, 0.082 g, 0.275 mmol) following the procedure described in Example 1.

δ $^1\text{H-NMR}$ (DMSO- d_6): 7.13-7.16 (m, 2H), 7.26 (s, 1H), 7.41-7.43 (m, 1H), 8.41-8.43 (m, 2H), 8.48-8.51 (m, 1H), 8.62 (s, 1H).

ESI/MS m/e: 324 ($[M+H]^+$, $C_{16}H_{10}ClN_5O$)

Example 27

Step a:



5


***N*-(6'-Amino-3''-chloro-4,2':3',4''-terpyridin-5'-yl)-4-fluorobenzamide**

Obtained (0.335 g, 95% of yield) from 3''-chloro-4,2':3',4''-terpyridine-5',6'-diamine (Intermediate 7, 0.250 g, 0.84 mmol) and 4-fluorobenzoyl chloride (0.120 mL, 1.01 mmol) following the procedure described in Example 2, step a. The crude mixture was used in

10

ESI/MS m/e: 420 ($[M+H]^+$, $C_{22}H_{15}ClFN_5O$)

Step b:



6-(3-Chloropyridin-4-yl)-2-(4-fluorophenyl)-5-pyridin-4-yl-3H-imidazo[4,5-b]pyridine

15


Obtained (0.099 g, 31% of yield) from *N*-(6'-amino-3''-chloro-4,2':3',4''-terpyridin-5'-yl)-4-fluorobenzamide (0.005 g, 0.8 mmol) following the procedure described in Example 2, step b.

δ 1H -NMR (DMSO- d_6): 7.25-7.28 (m, 2H), 7.41-7.54 (m, 3H), 8.08 (s, 1H), 8.30-8.37 (m, 2H), 8.46-8.49 (m, 2H), 8.54-8.56 (d, 1H), 8.64 (s, 1H).

20

ESI/MS m/e: 402 ($[M+H]^+$, $C_{22}H_{13}ClFN_5$)

Example 28



5-(3-Chloropyridin-4-yl)-2-(4-fluorophenyl)-6-(3-fluoropyridin-4-yl)-3H-imidazo[4,5-

25


b]pyridine

Following the same protocol as in Example 2, but using 4-fluorobenzoylchloride and 3-chloro-3''-fluoro-4,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 8**), the title compound was obtained as a white solid (13 mg, 12%).

ESI/MS m/e: 420 ([M+H]⁺, C₂₂H₁₂ClF₂N₅).

5

Example 29




5,6-Bis(3-chloropyridin-4-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one

Obtained (0.026 g, 84% of yield) from 3,3''-dichloro-4,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 9**, 0.029 g, 0.09 mmol) following the procedure described in Example 1.

10

ESI/MS m/e: 358 ([M+H]⁺, C₁₆H₉Cl₂N₅O)

Example 30



15 5-(1,3-Oxazol-2-yl)-6-pyridin-4-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one

A solution of 2-(1,3-oxazol-2-yl)-3,4'-bipyridine-5,6-diamine (**Intermediate 10**, 0.077g, 0.3 mmol), *N,N'*-carbonyldiimidazole (0.146 g, 0.9 mmol) and triethylamine (91 mg, 0.9 mmol) in *N,N*-dimethylformamide (1 mL) was heated to 100 °C in a sealed tube. After 4 hours, the mixture was cooled and concentrated in vacuo. Water was added to the residue and the solid that separated was washed with water and dried to give the title compound (0.038 g, 45%) as a white solid.


20

δ ¹H-NMR (DMSO-d₆): 7.21 (d, 2H), 7.29 (s, 1H), 8.08 (s, 1H), 8.51 (d, 2H), 11.39 (s, 1H), 11.78 (s, 1H).

ESI/MS m/e: 280 ([M+H]⁺, C₁₄H₉N₅O₂)

25

Example 31




5-(1,3-Oxazol-2-yl)-6-pyridin-4-yl-3H-imidazo[4,5-b]pyridine

A mixture of 2-(1,3-oxazol-2-yl)-3,4'-bipyridine-5,6-diamine (Intermediate 10, 0.100 g, 0.39 mmol) and triethylorthoformate (0.117 g, 0.79 mmol) in glacial acetic acid (2 mL) was heated in a sealed tube to 140 °C. After stirring for 2 hours, the mixture was cooled and
5 taken to pH 7 with 6N aqueous sodium hydroxide solution. Ethyl acetate was added to the mixture and, after stirring for 30 minutes, the separated solid was filtered, washed with diethyl ether and dried in vacuo to give the title compound (0.047 g, 49%) as an off-white solid.

δ ¹H-NMR (DMSO-d₆): 7.20 (m, 3H), 8.06 (m, 2H), 8.50 (d, 2H), 8.60 (s, 1H).


10 ESI/MS m/e: 264 ([M+H]⁺, C₁₄H₉N₅O)

Example 32**15 6-(3-Fluoropyridin-4-yl)-5-(1,3-oxazol-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one**

Obtained (37%) from 3'-fluoro-2-(1,3-oxazol-2-yl)-3,4'-bipyridine-5,6-diamine (Intermediate 11) and *N,N'*-carbonyldiimidazole following the procedure described for preparation of example 30.

δ ¹H-NMR (DMSO-d₆): 7.18 (s, 1H), 7.31 (s, 1H), 7.47 (dd, 1H), 8.12 (s, 1H), 8.49
20 (m, 2H), 11.36 (s, 1H), 11.85 (s, 1H).

ESI/MS m/e: 298 ([M+H]⁺, C₁₄H₈FN₅O₂)


Example 33**25 6-(3-Fluoropyridin-4-yl)-5-(1,3-oxazol-2-yl)-3H-imidazo[4,5-b]pyridine**

Obtained (26%) from 3'-fluoro-2-(1,3-oxazol-2-yl)-3,4'-bipyridine-5,6-diamine (Intermediate 11) and triethylorthoformate following the procedure described for preparation of example 31.

δ ^1H -NMR (DMSO- d_6): 7.21 (s, 1H), 7.53 (dd, 1H), 8.18 (m, 2H), 8.50 (m, 2H), 8.71 (s, 1H).

ESI/MS m/e: 282 ($[\text{M}+\text{H}]^+$, $\text{C}_{14}\text{H}_8\text{FN}_5\text{O}$)

5 Example 34




5-(1,3-Oxazol-5-yl)-6-pyridin-4-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one

Obtained (58%) from 2-(1,3-oxazol-5-yl)-3,4'-bipyridine-5,6-diamine (Intermediate 12) and N,N'-carbonyldiimidazole following the procedure described for preparation of example 30.

δ ^1H -NMR (DMSO- d_6): 6.92 (s, 1H), 7.20 (s, 1H), 7.30 (d, 2H), 8.24 (s, 1H), 8.58 (d, 2H), 11.21 (s, 1H), 11.69 (s, 1H).

ESI/MS m/e: 278 ($[\text{M}-\text{H}]^+$, $\text{C}_{14}\text{H}_9\text{N}_5\text{O}_2$)

15 Example 35




5-(1,3-oxazol-5-yl)-6-pyridin-4-yl-3H-imidazo[4,5-b]pyridine

Obtained (66%) from 2-(1,3-oxazol-5-yl)-3,4'-bipyridine-5,6-diamine (Intermediate 12) and triethylorthoformate following the procedure described for preparation of example 31.

δ ^1H -NMR (DMSO- d_6): 7.00 (m, 1H), 7.36 (m, 2H), 8.00 (m, 1H), 8.31 (s, 1H), 8.62 (m, 3H), 13.0 (s, 1H).

ESI/MS m/e: 264 ($[\text{M}+\text{H}]^+$, $\text{C}_{14}\text{H}_9\text{N}_5\text{O}$)

Example 36



6-(3-Fluoropyridin-4-yl)-5-(1,3-oxazol-5-yl)-3H-imidazo[4,5-b]pyridine


Obtained (25%) from 3'-fluoro-2-(1,3-oxazol-5-yl)-3,4'-bipyridine-5,6-diamine (Intermediate 13) and triethylorthoformate following the procedure described for preparation of example 31.

$\delta^1\text{H-NMR}$ (DMSO- d_6): 7.17 (s, 1H), 7.58 (dd, 1H), 8.15 (s, 1H), 8.32 (s, 1H), 8.55 (dd, 1H), 8.65 (m, 2H).

ESI/MS m/e : 282 ($[M+H]^+$, $C_{14}H_8FN_5O$)

Example 37

Step a:




***N*-(6'-Amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)-3-fluoro-4-methylbenzamide**

To a solution of 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.1 g, 0.356 mmol) in pyridine (2 mL), 0.15 g (0.89 mmol) of 3-fluoro-4-methylbenzoyl chloride were added. The mixture was stirred at room temperature overnight and the solvent was evaporated. The crude mixture (0.33 g) was purified by silica gel flash chromatography (95:5 dichloromethane/methanol) to give the title compound (0.12 g, 81% of yield).

ESI/MS m/e : 418 ($[M+H]^+$, $C_{23}H_{17}F_2N_5O$)

Step b:



2-(3-Fluoro-4-methylphenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine

A solution of *N*-(6'-amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)-3-fluoro-4-methylbenzamide (0.12 g, 0.288 mmol) in acetic acid (2 mL) was heated in a sealed tube at 118°C for 16h.


The solvent was evaporated and 4% sodium bicarbonate aqueous solution was added and extracted with ethyl acetate. The organic layer was dried and evaporated. The residue was purified by silica gel flash chromatography (95:5 dichloromethane/methanol) to give the title compound (0.03 g, 26% of yield).

δ $^1\text{H-NMR}$ (CDCl_3): 2.41 (s, 3H), 7.17-7.50 (m, 4H), 7.96 (m, 1H), 8.01 (s, 1H), 8.14 (s, 1H), 8.43 (d, 1H), 8.49 (dd, 1H), 8.65 (dd, 1H), 9.57 (m, 1H).

ESI/MS m/e : 400 ($[\text{M}+\text{H}]^+$, $\text{C}_{23}\text{H}_{15}\text{F}_2\text{N}_5$).

5 Example 38

Step a:




***N*-(6'-Amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)-3-fluorobenzamide**

Obtained (0.180 g) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 1**, 0.1 g, 0.356 mmol) and 3-fluorobenzoyl chloride (0.048 mL, 0.392 mmol) following the procedure described in Example 6, step a.

ESI/MS m/e : 404 ($[\text{M}+\text{H}]^+$, $\text{C}_{22}\text{H}_{15}\text{F}_2\text{N}_5\text{O}$)

Step b:




2-(3-Fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine

Obtained (0.035 g, 26% of yield) from *N*-(6'-amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)-3-fluorobenzamide following the procedure described in Example 37, step b.

δ $^1\text{H-NMR}$ (CDCl_3): 7.20 (m, 1H), 7.39 (m, 3H), 7.60 (td, 1H), 8.09 (m, 2H), 8.16 (s, 1H), 8.44 (s, 1H), 8.50 (d, 1H), 8.68 (dd, 1H), 9.73 (s, 1H).

ESI/MS m/e : 386 ($[\text{M}+\text{H}]^+$, $\text{C}_{22}\text{H}_{13}\text{F}_2\text{N}_5$).

Example 39



6-(3-Fluoropyridin-4-yl)-2,5-dipyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine


Obtained (0.025 g, 24% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 1**, 0.1 g, 0.356 mmol) and nicotinoyl chloride hydrochloride (0.070 g, 0.392 mmol) following the procedure described in Example 38.

5 δ ¹H-NMR (CDCl₃): 7.21 (m, 1H), 7.41 (m, 2H), 7.59 (m, 1H), 8.20 (s, 1H), 8.45 (s, 1H), 8.52 (m, 1H), 8.69 (s, 1H), 8.72 (s, 1H), 8.82 (m, 1H), 9.61 (m, 1H), 9.82 (m, 1H).

ESI/MS m/e: 369 ([M+H]⁺, C₂₁H₁₃FN₈).

Example 40

10 Step a:



***N*-(6'-Amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)pyrazine-2-carboxamide**


A solution of pyrazine-2-carboxylic acid (0.114 g, 0.924 mmol), *N*-[3-(dimethylamino)propyl]-*N'*-ethylcarbodiimide hydrochloride (0.178 g, 0.924 mmol) and 1*H*-1,2,3-benzotriazol-1-ol (0.096 g, 0.712 mmol) in DMF (6mL) was heated at 40°C for 15 minutes. Finally, 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 1**, 0.1 g, 0.356 mmol) in DMF (1 mL) was added and the mixture was stirred at room temperature overnight. The crude mixture was extracted between ethyl acetate and water. The organic layer was washed with 4% sodium bicarbonate aqueous solution and water, dried

15 (MgSO₄) and evaporated. The residue was purified by silica gel flash chromatography (90:10 dichloromethane/methanol) to give the title compound (0.057 g, 41% of yield).

20

ESI/MS m/e: 388 ([M+H]⁺, C₂₀H₁₄FN₇O).

Step b:




6-(3-Fluoropyridin-4-yl)-2-pyrazin-2-yl-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine

Obtained (0.016 g, 28% of yield) from *N*-(6'-amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)pyrazine-2-carboxamide following the procedure described in Example 37, step b.

δ $^1\text{H-NMR}$ (CDCl_3): 7.20-7.35 (m, 3H), 7.57 (m, 1H), 8.22 (s, 1H), 8.43 (m, 1H), 8.48 (d, 1H), 8.72-8.77 (m, 3H), 9.24 (m, 1H), 9.75 (d, 1H).

ESI/MS m/e : 370 ($[\text{M}+\text{H}]^+$, $\text{C}_{20}\text{H}_{12}\text{FN}_7$).

5 Example 41



3-[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-yl]benzonitrile

Obtained (0.11 g, 53% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.15 g, 0.534 mmol) and 3-cyanobenzoyl chloride (0.133 g, 0.803 mmol)


10 following the procedure described in Example 38.

δ $^1\text{H-NMR}$ (CDCl_3): 7.22 (m, 1H), 7.37-7.45 (m, 2H), 7.72-7.88 (m, 2H), 8.19 (s, 1H), 8.46 (d, 1H), 8.54 (d, 1H), 8.64 (d, 1H), 8.71 (m, 1H), 8.73 (m, 1H), 9.92 (m, 1H).

ESI/MS m/e : 393 ($[\text{M}+\text{H}]^+$, $\text{C}_{23}\text{H}_{13}\text{FN}_6$).

15

Example 42



3-[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-yl]benzoic acid


To a solution of 3-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-yl]benzonitrile (Example 41, 0.1 g, 0.255 mmol) in a mixture of THF/water 1:2.5 (0.83 mL), 37 % hydrogen chloride aqueous solution (1.07 mL) was added. The mixture was heated at 70°C for 4 days. After cooling at room temperature, the solid precipitated was filtered off to give the title compound (0.070 g, 67% of yield).

ESI/MS m/e : 412 ($[\text{M}+\text{H}]^+$, $\text{C}_{23}\text{H}_{14}\text{FN}_5\text{O}_2$).

25

Example 43

Step a:




***N*-(6'-Amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)pyrimidine-5-carboxamide**

A solution of pyrimidine-5-carboxylic acid (0.088 g, 0.709 mmol), *N*-[3-(dimethylamino)propyl]-*N'*-ethylcarbodiimide hydrochloride (0.136 g, 0.709 mmol) and 1H-1,2,3-benzotriazol-1-ol (0.072 g, 0.534 mmol) in DMF (4 mL) was heated at 40°C for 15 minutes. Finally, 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 1**, 0.15 g, 0.534 mmol) in DMF (4 mL) was added and the mixture was stirred at room temperature overnight. The crude mixture was extracted between ethyl acetate and water. The organic layer was washed with 4% sodium bicarbonate aqueous solution and water, dried (MgSO₄) and evaporated. The residue (0.2 g) was used in the next step without further purification.

ESI/MS *m/e*: 388 ([*M*+*H*]⁺, C₂₀H₁₄FN₇O).

Step b:




6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-pyrimidin-5-yl-3*H*-imidazo[4,5-*b*]pyridine

Obtained (0.024 g, 12% of yield) from *N*-(6'-amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)pyrimidine-5-carboxamide following the procedure described in Example 37, step b.

ESI/MS *m/e*: 370 ([*M*+*H*]⁺, C₂₀H₁₂FN₇).

Example 44




6-(3-Fluoropyridin-4-yl)-2-pyridin-2-yl-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine

Obtained (0.006 g, 18% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 1**, 0.1 g, 0.356 mmol) and pyridine-2-carbonyl chloride (0.131 g, 0.926 mmol) following the procedure described in Example 37.

ESI/MS m/e: 369 ([M+H]⁺, C₂₁H₁₃FN₆).

Example 45

Step a:




***N*-(6'-Amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)-3-chloroisonicotinamide**

A solution of 3-chloroisonicotinic acid (0.075 g, 0.48 mmol), *N*-[(dimethylamino)(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yloxy)methylene]-*N*-methylmethanaminium hexafluorophosphate (0.178 g, 0.47 mmol) and *N*-ethyl-*N*-isopropylpropan-2-amine (0.15 mL, 0.86 mmol) in DMF (1 mL) was stirred 15 minutes. Finally, 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 1**, 0.11 g, 0.39 mmol) in DMF (2.9 mL) was added and the mixture was stirred at room temperature 3.5 hours. The crude mixture was extracted between ethyl acetate and water. The organic layer was washed with water and brine, dried (MgSO₄) and evaporated. The residue (0.195 g) was used in the next step without further purification.

ESI/MS m/e: 421 ([M+H]⁺, C₂₁H₁₄ClFN₆O).

Step b:



2-(3-Chloropyridin-4-yl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine


Obtained (0.030 g, 16% of yield) from *N*-(6'-amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)-3-chloroisonicotinamide following the procedure described in Example 37, step b.

δ ¹H-NMR (CDCl₃): 7.19 (dd, 1H), 7.31 (t, 1H), 7.57 (d, 1H), 8.25 (m, 2H), 8.42 (s, 1H), 8.47 (d, 1H), 8.57 (dt, 1H), 8.73 (d, 1H), 8.82 (s, 1H), 9.11 (s, 1H).

ESI/MS m/e: 403 ([M+H]⁺, C₂₁H₁₂ClFN₆).

Example 46

Step a:




***N*-(6'-amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)-1-methyl-1*H*-imidazole-5-carboxamide**

Obtained (0.040 g, 19% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.15 g, 0.534 mmol) and 1-methyl-1*H*-imidazole-5-carboxylic acid (0.088 g, 0.694 mmol) following the procedure described in Example 41, step a.

ESI/MS *m/e*: 390 ($[M+H]^+$, C₂₀H₁₆FN₇O).

Step b:




6-(3-Fluoropyridin-4-yl)-2-(1-methyl-1*H*-imidazol-5-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine

A solution of *N*-(6'-amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)-1-methyl-1*H*-imidazole-5-carboxamide (0.040 g, 0.103 mmol) in acetic acid (1 mL) was heated in a sealed tube at 118°C for 16h. The solvent was evaporated and 4% sodium bicarbonate aqueous solution was added and extracted with ethyl acetate. The organic layer was dried and evaporated to give the title compound (0.022g, 58% of yield).

ESI/MS *m/e*: 372 ($[M+H]^+$, C₂₀H₁₄FN₇).

Example 47

Step a:



6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridine-2-thione


A solution of 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 2 g, 7.11 mmol), 1,1'-thiocarbonyldiimidazole (2.54 g, 14.22 mmol) and triethylamine (2 mL, 14.22 mmol) in

THF (30 mL) was heated at 80 °C in a sealed tube. After 6 hours, the mixture was cooled and the solid was filtrered, washed with NH₄Cl aq. and water and dried to give the title compound (2.03 g, 88%) as a white solid.

δ ¹H-NMR (DMSO-d₆): 7.31 (dd, 1H), 7.49 (dd, 1H), 7.58 (s, 1H), 7.64 (dt, 1H),
8.39-8.48 (m, 4H).

ESI/MS m/e: 324 ([M+H]⁺, C₁₆H₁₀FN₅S).

Step b:



10 6-(3-Fluoropyridin-4-yl)-2-(methylthio)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine


To a suspension of sodium hydride 60% (0.098 g, 2.45 mmols) in DMF (5 mL) a suspension of 6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-thione (0.6 g, 1.86 mmols) in DMF (15 mL) was added dropwise, at 0 °C, under argon. The solution was allowed to stir for 30 minutes at 0°C and then iodomethane (0.116 mL, 1.86 mmol) in DMF (1mL) was added dropwise. The reaction mixture was warmed up to room temperature and stirred for 2.5 hours. The mixture was concentrated and purified by silica gel flash chromatography (150:40:5 dichloromethane/methanol/ammonia) to give the title compound (0.34 g, 54% of yield).

δ ¹H-NMR (DMSO-d₆): 2.74 (s, 3H), 7.309 (dd, 1H), 7.51 (t, 1H), 7.66 (dt, 2H), 7.98 (s, 1H), 8.43-8.47 (m, 4H).

ESI/MS m/e: 338 ([M+H]⁺, C₁₇H₁₂FN₅S).

Example 48

Step a:




Ethyl 1-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-yl]-1H-pyrazole-4-carboxylate

A solution of 6-(3-fluoropyridin-4-yl)-2-(methylthio)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine (Example 47, 0.1 g, 0.3 mmol), ethyl 1H-pyrazole-4-carboxylate (0.125 g, 0.88 mmol) and potassium carbonate (0.164 mg, 1.18 mmol) in DMF (2 mL) was heated at 120°C in a sealed tube. After 2 days, the solvent was evaporated and the crude mixture was purified by silica gel flash chromatography (100:8:1 dichloromethane/methanol/ammonia) to give the title compound (0.034 g, 27% of yield).

ESI/MS m/e: 430 ([M+H]⁺, C₂₂H₁₆FN₇O₂).

Step b:




1-[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-yl]-1H-pyrazole-4-carboxylic acid

To a solution of ethyl 1-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-yl]-1H-pyrazole-4-carboxylate (0.022 g, 0.05 mmol) in a mixture of THF/ethanol 1:1 (1 mL), 2N sodium hydroxide aqueous solution (0.05 mL) was added. The mixture was heated at 60°C for 2 hours and then neutralised with 2N hydrogen chloride aqueous solution. The solvent was evaporated and the crude mixture was purified by solid phase extraction, SCX, it was washed with water and eluted with methanol/ammonia (9:1) to give the title compound (0.007g, 29% of yield).

ESI/MS m/e: 402 ([M+H]⁺, C₂₀H₁₂FN₇O₂).


Example 49



6-(3-Fluoropyridin-4-yl)-2-(1-methyl-1H-pyrazol-5-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine

Obtained (0.012 g, 24% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.2 g, 0.71 mmol), N,N-dicyclohexylcarbodiimide (0.19 g, 0.92 mmol), 1H-1,2,3-benzotriazol-1-ol (0.099 g, 0.73 mmol) and 1-methyl-1H-pyrazole-5-carboxylic acid (0.116 g, 0.92 mmol) following the procedure described in Example 41.

ESI/MS m/e: 372 ([M+H]⁺, C₂₀H₁₄FN₇).

Example 50

6-(3-Fluoropyridin-4-yl)-2-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine

Obtained (0.017 g, 24% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.085 g, 0.30 mmol), *N,N*-dicyclohexylcarbodiimide (0.074 g, 0.36 mmol), 1*H*-1,2,3-benzotriazol-1-ol (0.042 g, 0.31 mmol) and 1-methyl-3-(trifluoromethyl)-1*H*-pyrazole-5-carboxylic acid (0.071 g, 0.36 mmol) following the procedure described in


Example 41.

δ $^1\text{H-NMR}$ (DMSO- d_6): 4.45 (s, 3H), 7.33 (dd, 1H), 7.55-7.59 (m, 2H), 7.71 (dt, 1H), 8.31 (s, 1H), 8.48-8.50 (m, 4H).

ESI/MS m/e : 440 ($[\text{M}+\text{H}]^+$, $\text{C}_{21}\text{H}_{13}\text{F}_4\text{N}_7$).

Example 51

Step a:




6-(3-fluoropyridin-4-yl)-2-hydrazino-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine

A solution of 6-(3-fluoropyridin-4-yl)-2-(methylthio)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine (Example 47, 0.05 g, 0.15 mmol) in hydrazine (0.5 mL) was heated in a sealed tube at 100°C for 30 hours. The solvent was evaporated and the residue (0.05 g) was used in the next step without further purification.

ESI/MS m/e : 322 ($[\text{M}+\text{H}]^+$, $\text{C}_{16}\text{H}_{12}\text{FN}_7$).

Step b:




2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine

A solution of 6-(3-fluoropyridin-4-yl)-2-hydrazino-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine (0.05 g, 0.15 mmol), pentane-2,4-dione (0.016 mL, 0.16 mmol) and hydrogen chloride aqueous solution in ethanol (1 mL) was heated in a sealed tube at 80°C for 16 hours. The acidic pH was neutralized and then the solvent was evaporated and the crude mixture was purified by reverse phase chromatography (water/acetonitrile) to give the title compound (0.015 g, 25% of yield).

ESI/MS m/e: 386 ([M+H]⁺, C₂₁H₁₆FN₇).

Example 52

Step a:




15 N-(6'-Amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)-1H-1,2,4-triazole-3-carboxamide

A solution of 1H-1,2,4-triazole-3-carboxylic acid (0.072 g, 0.64 mmol), N-[(dimethylamino)(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methylmethanaminium hexafluorophosphate (0.243 g, 0.64 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.205 mL, 1.17 mmol) in DMF (1.5 mL) was stirred for 15 minutes under argon. Finally, 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 1**, 0.15 g, 0.53 mmol) in DMF (3 mL) was added and the mixture was stirred at room temperature for 20 hours. The solvent was evaporated and the crude mixture was purified by silica gel flash chromatography (90:10 dichloromethane/methanol) to give the title compound (0.070 g, 35% of yield).

ESI/MS m/e: 377 ([M+H]⁺, C₁₈H₁₃FN₈O).

Step b:



6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-(4H-1,2,4-triazol-3-yl)-3H-imidazo[4,5-b]pyridine


A solution of *N*-(6'-amino-3''-fluoro-3,2':3',4''-terpyridin-5'-yl)-1*H*-1,2,4-triazole-3-carboxamide (0.070 g, 0.19 mmol) in acetic acid (2.5 mL) was heated in a sealed tube at 120°C for 18h. The solvent was evaporated and the residue was suspended in ethyl acetate and 4% sodium bicarbonate aqueous solution. The solid formed was filtered and dried *in vacuo* to give the title compound (0.039g, 59% of yield).

δ ¹H-NMR (DMSO-*d*₆): 7.33 (m, 1H), 7.56 (m, 1H), 7.69 (m, 1H), 8.13 (m, 1H), 8.47 (m, 4H), 8.69 (m, 1H).

ESI/MS *m/e*: 359 ([*M*+*H*]⁺, C₁₈H₁₁FN₈).

Example 53

Step a:




6-(3-Fluoropyridin-4-yl)-2-(methylsulfonyl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine

To a solution of 6-(3-fluoropyridin-4-yl)-2-(methylthio)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine (Example 47, 0.096 g, 0.285 mmol) in DCM (6 mL) was added 3-chlorobenzenecarboxoperoxoic acid (0.128 g, 77% purity, 0.570 mmol) at 0°C. The reaction mixture was warmed up to room temperature and stirred for 16 h. The mixture was concentrated and purified by reverse phase chromatography (water/acetonitrile) to give the title compound (0.040 g, 38% of yield).

ESI/MS *m/e*: 370 ([*M*+*H*]⁺, C₁₇H₁₂FN₅O₂S).


Step b:



6-(3-Fluoropyridin-4-yl)-2-morpholin-4-yl-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine


A solution of 6-(3-fluoropyridin-4-yl)-2-(methylsulfonyl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine (0.025 g, 0.068 mmol), morpholine (0.024 mL, 0.268 mmol) in dioxane (0.5 mL) was heated in a sealed tube at 120°C overnight. The solvent was evaporated and the residue was purified by silica gel flash chromatography (95:5 dichloromethane/methanol) to give the title compound (0.011g, 44% of yield).

ESI/MS m/e: 377 ([M+H]⁺, C₂₀H₁₇FN₆O).

Example 54**6-(3-Fluoropyridin-4-yl)-2-piperidin-1-yl-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine**

A solution of 6-(3-fluoropyridin-4-yl)-2-(methylthio)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine (Example 47, 0.05 g, 0.15 mmol), piperidine (0.052 mL, 0.45 mmol) and acetic acid in xylene (1 mL) was heated at 120°C in a sealed tube. After 2 days, the solvent was evaporated and the crude mixture was purified by silica gel flash chromatography (95:5 dichloromethane/methanol) to give the title compound (0.03 g, 54% of yield).


ESI/MS m/e: 430 ([M+H]⁺, C₂₁H₁₉FN₆).

Example 55**6-(3-Fluoropyridin-4-yl)-2-(4-methylpiperazin-1-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine**

Obtained (0.045 g, 55% of yield) from 6-(3-fluoropyridin-4-yl)-2-(methylthio)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine (Example 47, 0.1 g, 0.3 mmol) and 1-methylpiperazine (0.117 mL, 1.05 mmol) following the procedure described in Example 57.

ESI/MS m/e: 390 ([M+H]⁺, C₂₁H₂₀FN₇).

Example 56**Step a:**




Ethyl [6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-yl]carbamate

Obtained (0.175 g, 87% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.15 g, 0.53 mmol) and ethyl isothiocyanatidocarbonate (0.094 mL, 0.8 mmol) following the procedure described in Example 19 (reaction time: 20 h).

δ $^1\text{H-NMR}$ (CDCl_3): 1.37 (t, 3H), 4.37 (q, 2H), 7.23 (m, 2H), 7.70 (d, 1H), 7.81 (s, 1H), 8.39 (m, 2H), 8.51 (d, 1H), 8.57 (m, 1H).

ESI/MS m/e : 379 ($[\text{M}+\text{H}]^+$, $\text{C}_{19}\text{H}_{15}\text{FN}_6\text{O}_2$).

10 Step b:




6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-amine

A solution of ethyl [6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-yl]carbamate (0.175 g, 0.46 mmol), potassium hydroxide (0.17 g, 3.01 mmol) in propan-2-ol (2 mL) was heated at 110°C for 24h. The solvent was evaporated and the crude mixture (0.38 g) was purified by reverse phase chromatography (water/acetonitrile) to give the title compound (0.08 g, 57% of yield).

δ $^1\text{H-NMR}$ (DMSO-d_6): 6.98 (s, 1H), 7.26 (dd, 1H), 7.42 (m, 2H), 7.62 (dt, 1H), 8.36-8.41 (m, 3H).

ESI/MS m/e : 307 ($[\text{M}+\text{H}]^+$, $\text{C}_{16}\text{H}_{11}\text{FN}_6$).

Example 57




6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-[3-(trifluoromethyl)benzyl]-3H-imidazo[4,5-b]pyridine

Obtained (0.026 g, 42% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.1 g, 0.356 mmol) and [3-(trifluoromethyl)phenyl]acetyl chloride (0.075 g, 0.337 mmol) following the procedure described in Example 37.

5 δ ¹H-NMR (CDCl₃): 4.47 (s, 2H), 7.04-7.11 (m, 1H), 7.25-7.60 (m, 6H), 7.66 (s, 1H), 8.04 (s, 1H), 8.26 (d, 1H), 8.40 (m, 1H), 8.46 (d, 1H), 9.31 (s, 1H).
ESI/MS m/e: 450 ([M+H]⁺, C₂₄H₁₅F₄N₅).

Example 58




10 6-(3-Fluoropyridin-4-yl)-2-(2-phenylethyl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine

Obtained (0.060 g, 49% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.1 g, 0.356 mmol) and 3-phenylpropanoyl chloride (0.080 mL, 0.534 mmol) following the procedure described in Example 37.

15 δ ¹H-NMR (CDCl₃): 3.24 (m, 4H), 7.11 (dd, 1H), 7.20-7.33 (m, 6H), 7.46 (d, 1H), 8.04 (s, 1H), 8.40 (d, 1H), 8.45 (d, 1H), 8.49 (dd, 1H), 9.23 (s, 1H), 12.76 (s, 1H).
ESI/MS m/e: 396 ([M+H]⁺, C₂₄H₁₈FN₅).

Example 59




20 6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-(2-pyridin-3-ylethyl)-3H-imidazo[4,5-b]pyridine

Obtained (0.02 g, 59% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.1 g, 0.356 mmol) and 3-pyridin-3-ylpropanoic acid (0.070 g, 0.463 mmol) following the procedure described in Example 41.

25 δ ¹H-NMR (CDCl₃): 3.29 (s, 4H), 7.23 (m, 3H), 7.61 (d, 2H), 8.00 (s, 1H), 8.37 (d, 1H), 8.40 (d, 1H), 8.45 (m, 1H), 8.52 (d, 1H), 8.54 (d, 1H), 8.65 (d, 1H).
ESI/MS m/e: 397 ([M+H]⁺, C₂₃H₁₇FN₆).

Example 60



2-[1-(4-Chlorophenyl)ethyl]-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridine


Obtained (0.035 g, 52% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.15 g, 0.534 mmol) and 2-(4-chlorophenyl)propanoic acid (0.128 g, 0.694 mmol) following the procedure described in Example 41.

δ $^1\text{H-NMR}$ (CDCl_3): 1.91 (d, 3H), 4.51 (q, 1H), 7.08 (m, 1H), 7.30 (m, 5H), 7.39 (m, 1H), 8.07 (s, 1H), 8.28 (dd, 1H), 8.41 (d, 1H), 8.47 (d, 1H), 9.24 (d, 1H), 12.58 (s, 1H).

ESI/MS m/e : 430 ($[\text{M}+\text{H}]^+$, $\text{C}_{24}\text{H}_{17}\text{ClFN}_5$).

Example 61

Step a:




4-[2-(6'-Amino-3''-fluoro-[3,2';3',4'']terpyridin-5'-ylcarbamoyl)-ethyl]-benzoic acid *tert*-butyl ester

Obtained (0.135 g, 49% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.15 g, 0.534 mmol) and 3-[4-(*tert*-butoxycarbonyl)phenyl]propanoic acid (0.174 g, 0.694 mmol) following the procedure described in Example 41, step a:

ESI/MS m/e : 514 ($[\text{M}+\text{H}]^+$, $\text{C}_{29}\text{H}_{28}\text{FN}_5\text{O}_3$).

Step b:




4-{2-[6-(3-Fluoro-pyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-yl]-ethyl}-benzoic acid

A solution of 4-[2-(6'-Amino-3"-fluoro-[3,2':3',4'']terpyridin-5'-ylcarbamoyl)-ethyl]-benzoic acid *tert*-butyl ester (0.135 g, 0.263 mmol) in acetic acid (2 mL) was heated in a sealed tube at 118°C for 16h. The solvent was evaporated and ethyl acetate was added. The solid formed was filtrered and washed with 4% sodium bicarbonate aqueous solution,
 5 water and dried to give the title compound (0.08g, 69% of yield).

ESI/MS m/e: 440 ($[M+H]^+$, $C_{25}H_{18}FN_5O_2$).

Example 62




10 6-(3-Fluoropyridin-4-yl)-N,5-dipyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-amine

To a solution of 3"-fluoro-3,2':3',4'"-terpyridine-5',6'-diamine (**Intermediate 1**, 0.1 g, 0.356 mmol) and 3-isothiocyanatopyridine (0.06 mL, 0.534 mmol) in ethanol (2 mL), 1,3-diisopropylcarbodiimide (0.083 mL, 0.534 mmol) was added. The mixture was heated at 50°C for 2h. After cooling at room temperature, the solvent was evaporated. The crude
 15 mixture was purified by silica gel flash chromatography (95:5 dichloromethane/methanol) to give the title compound (0.045 g, 33% of yield).

ESI/MS m/e: 384 ($[M+H]^+$, $C_{21}H_{14}FN_7$).

Example 63




20

N-(4-Fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3H-imidazo[4,5-b]pyridin-2-amine

Obtained (0.048 g, 49% of yield) from 3"-fluoro-3,2':3',4'"-terpyridine-5',6'-diamine (**Intermediate 1**, 0.15 g, 0.534 mmol) and 1-fluoro-4-isothiocyanatobenzene (0.082 g,
 25 0.534 mmol) following the procedure described in Example 62.

δ 1H -NMR (DMSO- d_6): 7.19 (t, 2H), 7.30 (dd, 1H), 7.47 (dd, 1H), 7.63-7.69 (m, 2H), 7.80-7.87 (m, 2H), 8.43 (m, 4H).


ESI/MS m/e: 401 ($[M+H]^+$, $C_{22}H_{14}F_2N_6$).

Example 64**Step a:**

5 **4-[6-(3-Fluoro-pyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-ylamino]-benzoic acid ethyl ester**

Obtained (0.120 g, 74% of yield) from 3''-fluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 1, 0.10 g, 0.356 mmol) and ethyl 4-isothiocyanatobenzoate (0.111 g, 0.534 mmol) following the procedure described in Example 62.


10 ESI/MS *m/e*: 455 ([*M*+*H*]⁺, C₂₅H₁₉FN₆O₂).

Step b:

15 **4-{[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]amino}benzoic acid**

To a solution of 4-[6-(3-fluoro-pyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-ylamino]-benzoic acid ethyl ester (0.120 g, 0.264 mmol) in ethanol (3.5 mL), 2N sodium hydroxide aqueous solution (0.53 mL) was added. The mixture was stirred at room temperature overnight and then neutralised with 2N hydrogen chloride aqueous solution. The solvent was evaporated and the crude mixture (0.18 g) was purified by reverse phase chromatography (water/acetonitrile) to give the title compound (0.02g, 18% of yield).

20 ESI/MS *m/e*: 427 ([*M*+*H*]⁺, C₂₃H₁₅FN₆O₂).

Example 65


6-(3,5-Difluoropyridin-4-yl)-2-(4-fluorophenyl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine

Obtained (0.037 g, 20% of yield) from 3'',5''-difluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 14, 0.10 g, 0.33 mmol) and 4-fluorobenzoyl chloride (0.059 mL, 0.5 mmol) following the procedure described in Example 37.

ESI/MS *m/e*: 404 ([*M*+*H*]⁺, C₂₂H₁₂F₃N₅).

Example 66

Step a:




Methyl 4-[6-(3,5-difluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]benzoate

Obtained (0.050 g, 70% of yield) from 3'',5''-difluoro-3,2':3',4''-terpyridine-5',6'-diamine (Intermediate 14, 0.10 g, 0.33 mmol) and 4-(methoxycarbonyl)benzoic acid (0.078 g, 0.43 mmol) following the procedure described in Example 41.

ESI/MS *m/e*: 404 ([*M*+*H*]⁺, C₂₂H₁₂F₃N₅).

Step b:




4-[6-(3,5-Difluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]benzoic acid

To a solution of methyl 4-[6-(3,5-difluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]benzoate (0.05 g, 0.11 mmol) in ethanol (1.1 mL), 2N sodium hydroxide aqueous solution (0.11 mL) was added. The mixture was heated at 60°C for 5.5 h and then neutralised with 2N hydrogen chloride aqueous solution. The solvent was evaporated and the crude mixture was suspended in water, the solid formed was filtered and dried to give the title compound (0.04 g, 76% of yield).

δ ¹H-NMR (MeOD): 7.41 (m, 1H), 7.86 (m, 1H), 8.22-8.33 (m, 5H), 8.42 (s, 2H), 8.50 (s, 1H), 8.57 (s, 1H).

ESI/MS m/e: 430 ($[M+H]^+$, $C_{23}H_{13}F_2N_5O_2$).

Example 67



- 5 **6-(3,5-Difluoropyridin-4-yl)-5-pyridin-3-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one**
 A solution of 3'',5''-difluoro-3,2':3',4''-terpyridine-5',6'-diamine (**Intermediate 14**, 0.045 g, 0.15 mmol), *N,N'*-carbonyldiimidazole (0.1 g, 0.6 mmol) and triethylamine (0.084 mL, 0.6 mmol) in THF (1.5 mL) was heated at 80 °C in a sealed tube. After 72 hours, the mixture was cooled and the solid was separated, washed with THF and dried to give the title
 10 compound (0.029 g, 59% of yield).

δ 1H -NMR (DMSO- d_6): 7.30 (dd, 1H), 7.44 (s, 1H), 7.61 (d, 1H), 8.38 (d, 1H), 8.46 (dd, 1H), 8.50 (s, 2H).

ESI/MS m/e: 326 ($[M+H]^+$, $C_{16}H_9F_2N_5O$).

15 COMPOSITION EXAMPLE 1

50,000 capsules, each containing 100 mg 5-(3-Fluoropyridin-4-yl)-6-pyridin-4-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (active ingredient), were prepared according to the following formulation:

20

Active ingredient	5 Kg
Lactose monohydrate	10 Kg
Colloidal silicon dioxide	0.1 Kg
Corn starch	1 Kg
Magnesium stearate	0.2 Kg

Procedure

- 25 The above ingredients were sieved through a 60 mesh sieve, and were loaded into a suitable mixer and filled into 50,000 gelatine capsules.

COMPOSITION EXAMPLE 2

- 50,000 tablets, each containing 50 mg of 5-(3-Fluoropyridin-4-yl)-6-pyridin-4-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one (active ingredient), were prepared from the
- 5 following formulation:


Active ingredient	2.5 Kg
Microcrystalline cellulose	1.95 Kg
Spray dried lactose	9.95 Kg
Carboxymethyl starch	0.4 Kg
Sodium stearyl fumarate	0.1 Kg
Colloidal silicon dioxide	0.1 Kg

Procedure

- 10 All the powders were passed through a screen with an aperture of 0.6 mm, then mixed in a suitable mixer for 20 minutes and compressed into 300 mg tablets using 9 mm disc and flat bevelled punches. The disintegration time of the tablets was about 3 minutes.

CLAIMS

1. A compound of formula (I)



5 wherein:

A represents a monocyclic nitrogen-containing heteroaryl group optionally substituted by one or more substituents independently selected from the group comprising halogen atoms, C₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₄alkyl, C₁₋₄alkoxy, aryl-C₁₋₄alkoxy, C₁₋₄alkylthio, mono or di-C₁₋₄alkylamino, trifluoromethyl, hydroxy and cyano groups;

B represents a monocyclic nitrogen-containing heteroaryl group optionally substituted by one or more substituents independently selected from the group comprising halogen atoms, C₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₄alkyl, C₁₋₄alkoxy, aryl-C₁₋₄alkoxy, C₁₋₄alkylthio, mono or di-C₁₋₄alkylamino, trifluoromethyl, hydroxy and cyano groups;

L represents a linking group selected from the group comprising direct bond, -(CRR')_n, -NR-, -S-, -O- and -CO-; wherein n is an integer from 0 to 2;

G represent a group selected from the group comprising -H, -OH, C₃₋₇ cycloalkyl; C₁₋₆ alkyl, aryl, heteroaryl and nitrogen-containing saturated heterocyclic rings, wherein the aryl, heteroaryl and nitrogen-containing saturated heterocyclic groups are unsubstituted or substituted by one or more groups selected from halogen atoms, C₁₋₄ alkyl, C₁₋₄ alkylthio, C₁₋₄ alkoxy, mono- or di-C₁₋₄ alkylamino, cyano, trifluoromethyl, -COOH and -CO-O-C₁₋₄ alkyl groups;

R and R' are independently selected from hydrogen atoms and C₁₋₄ alkyl groups;

and the pharmaceutically acceptable salts and N-oxides thereof.

2. A compound according to claim 1 wherein A represents an optionally substituted pyridine or an optionally substituted oxazole group.

3. A compound according to any preceding claim wherein the group A represents a pyridine ring either unsubstituted or substituted with one halogen atom.
4. A compound according to any preceding claim wherein B represents an optionally substituted pyridine or pyrimidine group.
5. A compound according to claim 4 wherein B represents a pyridine group which is unsubstituted or substituted by one or more halogen atoms.
6. A compound according to any preceding claim wherein -L-G represents a moiety selected from the group comprising of hydrogen atoms, hydroxyl groups, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted benzyl, optionally substituted benzoyl, C₃₋₇ cycloalkyl, C₁₋₆ alkyl, optionally substituted morpholino, optionally substituted piperidino and optionally substituted piperazine groups wherein optionally substituted groups may carry from 0 to 2 substituents selected from the group consisting of halogen atoms, C₁₋₄alkyl, C₁₋₄alkylthio, C₁₋₄alkoxy, mono or di-C₁₋₄alkylamino, cyano, - (CO)OH, -(CO)O-C₁₋₄alkyl, trifluoromethyl, piperidinylmethyl, pyridinylmethyl, phenylamino and piperidinylamino.
7. A compound according to claim 1 which is one of:
 - 6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
 - 2-Cyclopropyl-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
 - 2-Cyclohexyl-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
 - 6-(3-Fluoropyridin-4-yl)-2-methyl-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
 - 2-(4-Fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
 - 6-(3-Fluoropyridin-4-yl)-2-(4-methoxyphenyl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
 - N*-{4-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]phenyl}-*N,N*-dimethylamine
 - 6-(3-Fluoropyridin-4-yl)-2-(4-*tert*-butylphenyl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
 - 6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-[4-(trifluoromethyl)phenyl]-3*H*-imidazo[4,5-*b*]pyridine
 - Methyl 4-[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]benzoate
 - 4-[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]benzoic acid
 - 6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-pyridin-4-yl-3*H*-imidazo[4,5-*b*]pyridine

- 2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
- 6-(3-Fluoropyridin-4-yl)-2-[3-fluoro-4-(trifluoromethyl)phenyl]-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
- 5 2-(2,4-Dichloro-5-fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
- 2-(4-Fluorobenzyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
- 2-[1-(4-Chlorophenyl)-1-methylethyl]-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
- 10 (3,5-Difluorophenyl)[6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]methanone
- N*-(4-chlorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-amine
- 2-(4-Fluorophenyl)-5-pyridin-3-yl-6-pyridin-4-yl-3*H*-imidazo[4,5-*b*]pyridine
- 6-(3-Chloropyridin-4-yl)-5-pyridin-3-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 15 5,6-Dipyridin-4-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 5-(3-Fluoropyridin-4-yl)-6-pyridin-4-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 5-(3-Chloropyridin-4-yl)-6-pyridin-4-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 5-(3-Chloropyridin-4-yl)-2-(4-fluorophenyl)-6-pyridin-4-yl-3*H*-imidazo[4,5-*b*]pyridine
- 6-(3-Chloropyridin-4-yl)-5-pyridin-4-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 20 6-(3-Chloropyridin-4-yl)-2-(4-fluorophenyl)-5-pyridin-4-yl-3*H*-imidazo[4,5-*b*]pyridine
- 5-(3-Chloropyridin-4-yl)-2-(4-fluorophenyl)-6-(3-fluoropyridin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine
- 5,6-Bis(3-chloropyridin-4-yl)-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 5-(1,3-Oxazol-2-yl)-6-pyridin-4-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 25 5-(1,3-Oxazol-2-yl)-6-pyridin-4-yl-3*H*-imidazo[4,5-*b*]pyridine
- 6-(3-Fluoropyridin-4-yl)-5-(1,3-oxazol-2-yl)-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 6-(3-Fluoropyridin-4-yl)-5-(1,3-oxazol-2-yl)-3*H*-imidazo[4,5-*b*]pyridine
- 5-(1,3-Oxazol-5-yl)-6-pyridin-4-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one
- 5-(1,3-Oxazol-5-yl)-6-pyridin-4-yl-3*H*-imidazo[4,5-*b*]pyridine
- 30 6-(3-Fluoropyridin-4-yl)-5-(1,3-oxazol-5-yl)-3*H*-imidazo[4,5-*b*]pyridine
- 2-(3-Fluoro-4-methylphenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine.
- 2-(3-Fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
- 6-(3-Fluoropyridin-4-yl)-2,5-dipyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
- 35 6-(3-Fluoropyridin-4-yl)-2-pyrazin-2-yl-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine

- 3-[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]benzonitrile
3-[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]benzoic acid;
6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-pyrimidin-5-yl-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-2-pyridin-2-yl-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
5 2-(3-Chloropyridin-4-yl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-2-(1-methyl-1*H*-imidazol-5-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-2-(methylthio)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
1-[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]-1*H*-pyrazole-4-
10 carboxylic acid
6-(3-Fluoropyridin-4-yl)-2-(1-methyl-1*H*-pyrazol-5-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-2-[1-methyl-3-(trifluoromethyl)-1*H*-pyrazol-5-yl]-5-pyridin-3-yl-3*H*-
imidazo[4,5-*b*]pyridine
15 2-(3,5-Dimethyl-1*H*-pyrazol-1-yl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-(4*H*-1,2,4-triazol-3-yl)-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-2-morpholin-4-yl-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-2-piperidin-1-yl-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
20 6-(3-Fluoropyridin-4-yl)-2-(4-methylpiperazin-1-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-amine
6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-[3-(trifluoromethyl)benzyl]-3*H*-imidazo[4,5-*b*]pyridine
6-(3-Fluoropyridin-4-yl)-2-(2-phenylethyl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
25 6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-2-(2-pyridin-3-ylethyl)-3*H*-imidazo[4,5-*b*]pyridine
2-[1-(4-Chlorophenyl)ethyl]-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
4-{2-[6-(3-Fluoro-pyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]-ethyl}-benzoic
acid
6-(3-Fluoropyridin-4-yl)-*N*,5-dipyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-amine
30 *N*-(4-Fluorophenyl)-6-(3-fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-amine
4-[[6-(3-Fluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]amino}benzoic acid
6-(3,5-Difluoropyridin-4-yl)-2-(4-fluorophenyl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridine
4-[6-(3,5-Difluoropyridin-4-yl)-5-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-2-yl]benzoic acid
6-(3,5-Difluoropyridin-4-yl)-5-pyridin-3-yl-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one

8. A compound according to any one of claims 1 to 7 for use in the treatment of a pathological condition or disease susceptible to amelioration by antagonism of the adenosine A_{2B} receptor.
- 5 9. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 7 in association with a pharmaceutically acceptable diluent or carrier.
10. Use of a compound as defined in any one of claims 1 to 7 in the manufacture of a medicament for the treatment of a pathological condition or disease susceptible of being
10 improved by antagonism of the A_{2B} adenosine receptor.
11. Use according to claim 10, wherein the pathological condition or disease is asthma, bronchoconstriction, allergic diseases, hypertension, atherosclerosis, reperfusion injury, myocardial ischemia, retinopathy, inflammation, gastrointestinal tract disorders, cell
15 proliferation disorders, diabetes mellitus, and/or autoimmune diseases.
12. A method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A_{2B} adenosine receptor, which comprises administering to said subject an effective amount of a compound as defined in any one of
20 claims 1 to 7.
13. A method according to claim 12, wherein the pathological condition or disease is asthma, bronchoconstriction, allergic diseases, hypertension, atherosclerosis, reperfusion injury, myocardial ischemia, retinopathy, inflammation, gastrointestinal tract disorders, cell
25 proliferation disorders, diabetes mellitus, and/or autoimmune diseases.
14. A combination product comprising:
- (i) a compound according to any one of claims 1 to 7; and
- (ii) another compound selected from (1) antagonists of M3 muscarinic
30 receptors, (2) β 2-agonists, (3) PDE4 inhibitors, (4) corticosteroids, (5) leukotriene D4 antagonists, (6) inhibitors of egfr-kinase, (7) p38 kinase inhibitors, (8) NK1 receptor agonists, (9) CRTh2 antagonists, (10) syk kinase inhibitors, (11) CCR3 antagonists and (12) VLA-4 antagonists
for simultaneous, separate or sequential use in the treatment of the human or animal
35 body.

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2006/009620

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D471/04 A61K31/437 A61P37/00 A61P9/00 A61P3/10
A61P11/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 03/002566 A (CV THERAPEUTICS, INC; PALLE, VENKATA; VARKHEDKAR, VAIBHAV; ZABLOCKI, J) 9 January 2003 (2003-01-09) cited in the application the whole document	1-14
A	WO 03/068773 A (GLAXO GROUP LIMITED; WITHERINGTON, JASON) 21 August 2003 (2003-08-21) claims; example 39	1-14
A	EP 1 221 444 A (EISAI CO., LTD) 10 July 2002 (2002-07-10) claims; examples 61-63	1-14
A	& WO 01/02400 A 11 January 2001 (2001-01-11) cited in the application	
	-/--	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

2 January 2007

Date of mailing of the international search report

09/01/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bosma, Peter

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/009620

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2005/100353 A1 (ALMIRALL PRODESFARMA, SA, SPAIN; VIDAL JUAN, BERNAT) 27 October 2005 (2005-10-27) claims; examples -----	1-14

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2006/009620

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 12 and 13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2006/009620

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03002566	A	09-01-2003	AT 307132 T CA 2451244 A1 DE 60206756 T2 DK 1401837 T3 EP 1401837 A1 ES 2247356 T3 HK 1064096 A1 JP 2004536102 T	15-11-2005 09-01-2003 13-07-2006 07-11-2005 31-03-2004 01-03-2006 16-12-2005 02-12-2004
WO 03068773	A	21-08-2003	AU 2003245700 A1	04-09-2003
EP 1221444	A	10-07-2002	AT 303387 T AU 778450 B2 AU 5571700 A CA 2376835 A1 CN 1365361 A DE 60022366 D1 DE 60022366 T2 DK 1221444 T3 WO 0102400 A1 NZ 516260 A PT 1221444 T US 6841549 B1	15-09-2005 09-12-2004 22-01-2001 11-01-2001 21-08-2002 06-10-2005 14-06-2006 14-11-2005 11-01-2001 27-08-2004 30-11-2005 11-01-2005
WO 0102400	A	11-01-2001	AT 303387 T AU 778450 B2 AU 5571700 A CA 2376835 A1 CN 1365361 A DE 60022366 D1 DE 60022366 T2 DK 1221444 T3 EP 1221444 A1 NZ 516260 A PT 1221444 T US 6841549 B1	15-09-2005 09-12-2004 22-01-2001 11-01-2001 21-08-2002 06-10-2005 14-06-2006 14-11-2005 10-07-2002 27-08-2004 30-11-2005 11-01-2005
WO 2005100353	A1	27-10-2005	AR 049018 A1 AU 2005233279 A1 CA 2562369 A1 EP 1735310 A1 ES 2241496 A1	21-06-2006 27-10-2005 27-10-2005 27-12-2006 16-10-2005